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ABSTRACT 
 
Introduction  Circulating levels, and the ex vivo production, of the chemokines 
CCL3, CCL4, CCL5, CXCL8 and CXCL12 (known to play an important role in 
the pathogenesis of either human immunodeficiency virus type 1 (HIV-1) or 
tuberculosis (TB)) were examined in the context of both single infections with 
HIV-1 or Mycobacterium tuberculosis (Mtb) and coinfection with both 
organisms.  We hypothesised that CCL3L1 gene copy number (known to affect 
CCL3 production, associated with susceptibility to and disease progression of 
HIV-1) would be associated with mother-to-child transmission (MTCT) of HIV-1, 
and that the IL8-251T→A single nucleotide polymorphism (SNP) (associated 
with enhanced CXCL8 production and susceptibility to TB in African Americans) 
would be highly represented in the South African Black population. 
Methods  Samples used included (i) plasma, DNA samples and cell culture 
supernatants from control, HIV-1, TB and HIV-1/TB groups, (ii) DNA samples 
from mothers and their infants (grouped as HIV-1 exposed-uninfected, infected 
in utero, or infected intrapartum), and (iii) DNA samples from a population-
based study cohort.  Chemokines were quantified by enzyme-linked 
immunosorbent assay (ELISA), CCL3L1 gene copy numbers were determined 
by real-time polymerase chain reaction (PCR), and a real-time PCR method 
was developed for identification of the IL8-251T→A SNP.  DNA sequencing was 
used for confirmation. 
Results  We found reduced ex vivo chemokine production in response to 
phytohaemagglutinin (PHA) together with increased plasma levels of 
chemokines in HIV-1 and TB patients.  In contrast to that seen in Caucasians 
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(median CCL3L1 copy number of 2), in Black individuals (median CCL3L1 copy 
number of 5) circulating levels of CCL3 did not correlate with CCL3L1 gene 
copy number; in addition, a high proportion of Black individuals were found to 
have CCL3L1 copy numbers below their population-specific median.  Using 
MTCT as a model for studying HIV-1 transmission, infants who became infected 
with HIV-1 had significantly reduced CCL3L1 gene copy numbers.  IL8-251A 
allele frequencies were found to be 0.41 for Caucasian groups, and 0.85 for 
Black groups; due to study limitations, the possible association of IL8-251T→A 
with TB susceptibility could not be addressed. 
Discussion  The increased plasma levels of chemokines seen in HIV-1 and TB, 
likely due to chronic immune activation in vivo, may result in T cell anergy which 
in turn might be the cause of reduced PHA-stimulated ex vivo chemokine 
production.  Our results suggest that Black South Africans may be at particularly 
high risk for acquiring HIV-1 (at least with respect to CCL3L1 gene copy 
number), and further imply the presence of other genetic polymorphisms which 
may influence plasma CCL3 levels.  In addition, the high IL8-251A allele 
frequency (if indeed associated with TB in South African populations) in Black 
individuals suggests a greater risk for infection with Mtb.  It will be important, in 
larger studies, to gain a more in-depth understanding of the relationships 
between host genotype and chemokine production phenotype, and to relate 
these measures to infection outcomes. 
Conclusions  Together, these results highlight the importance of gaining an 
understanding of the effects of host genotype on the development of innate and 
acquired immunity to HIV-1 and TB, which will be key in the design of efficient 
therapies and prevention strategies. 
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CHAPTER 1 
 
INTRODUCTION 
 
 
1.1 The twin epidemics of HIV-1 and TB 
 
1.1.1 The HIV-1 pandemic 
 
Human Immunodeficiency Virus or HIV (a lentivirus of the retrovirus family; 
Figure 1), in particular HIV-1, and Acquired Immune Deficiency Syndrome or 
AIDS (refer to Appendix A for a full list of abbreviations) are growing problems 
world-wide, with sub-Saharan Africa the region by far the hardest hit.  In 2007, 
according to UNAIDS (http://www.unaids.org/en/), 68% of adults and nearly 
90% of children infected with HIV world-wide were living in sub-Saharan Africa, 
32% in southern Africa alone.  In addition, sub-Saharan Africa accounted for 
76% of all deaths due to AIDS in 2007 (Figure 2). 
 
The primary risk factors for HIV-1 infection are unprotected sexual intercourse, 
sharing of syringes, and receiving contaminated blood products.  Infants born to 
infected mothers comprise another group at high risk.   
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Figure 1   
Organisation of the HIV-1 virion. 
(from http://en.wikipedia.org/wiki/Hiv) 
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Figure 2   
Global HIV-1 estimates for adults and children, 2007. 
Estimates for people living with HIV-1 are shown in red, new HIV-1 infections in 
blue, and deaths due to AIDS in green. 
(adapted from UNAIDS; 
http://data.unaids.org/pub/EPISlides/2007/2007_epiupdate_en.pdf) 
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1.1.1.1 Mechanisms of infection by HIV-1 
 
When HIV-1 binds to its receptor CD4, the envelope glycoprotein gp120 
undergoes conformational changes.  This results in the exposure of previously 
buried gp120 domains which then interact with one of the HIV-1 coreceptors 
CCR5 and CXCR4, which stabilises virus binding (Amara et al., 1997), leading 
to membrane fusion mediated by gp41.  Inside the cell, viral RNA is reverse 
transcribed within the cytoplasm, whereupon the preintegration complex moves 
to the nucleus.  Within the nucleus, viral cDNA is integrated as provirus into the 
host genome.  New virions bud from the surface of infected cells in vivo a 
minimum of 1.2 days on average after infection (Perelson et al., 1996) (Figure 
3). 
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Figure 3   
HIV-1 lifecycle. 
(from http://en.wikipedia.org/ wiki/Hiv) 
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1.1.2 The TB epidemic 
 
Tuberculosis or TB, caused by the Mycobacterium tuberculosis (Mtb) bacillus 
(Figure 4) has been declared "a global health emergency" by the World Health 
Organisation (WHO) – around 2 billion people worldwide (a third of the world's 
population) are infected, with 8–10 million people becoming infected each year 
(Figure 5).  There are 2 million deaths annually as a result of TB, although 
around 90% of people infected with Mtb never develop the active disease, in the 
absence of HIV-1.   In a pattern similar to that seen for HIV-1, the major burden 
of TB falls on sub-Saharan Africa (Figure 6). 
 
 
 
 
Figure 4   
Scanning electron micrograph of Mycobacterium tuberculosis. 
(from http://en.wikipedia.org/ wiki/Tuberculosis) 
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Figure 5   
Annual number of new reported TB cases. 
(from http://en.wikipedia.org/wiki/Tuberculosis) 
 
 
 
 
Figure 6   
World TB incidence (2006).   
Cases per 100,000; red >300, orange 200-300; yellow 100-200; dark green 50-
100 and light green <50. 
(from http://en.wikipedia.org/wiki/Tuberculosis) 
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The TB epidemic has become of even greater concern with the emergence first 
of multi-drug resistant strains of Mtb (MDR-TB), and, more recently, extreme (or 
extensive) drug resistance (XDR-TB) (http://www.who.int/tb/en/).  MDR-TB is 
defined as having resistance to at least isoniazid and rifampicin, while XDR-TB 
is resistant to rifampicin and isoniazid, as well as to any fluoroquinolone and at 
least one of three second-line injectable drugs (kanamycin, amikacin and 
capreomycin); this makes XDR-TB almost impossible to treat.  In KwaZulu Natal 
in August 2006, of 53 patients diagnosed with XDR-TB, 52 died on average 
within 25 days (http://www.who.int/tb/xdr/xdrmap_20june_en.pdf).  Both MDR-
TB and XDR-TB are a world-wide problem – WHO figures show that of 17 690 
TB isolates tested between 2000 and 2004 in 49 countries, 20% were MDR-TB 
and 2% XDR-TB (http://www.who.int/tb/xdr/xdrmap_20june_en.pdf). 
 
Furthermore, cases of TB resistant to all known drugs have recently been 
described in Italy, with worrying implications (Migliori et al., 2007). 
 
1.1.2.1 Mechanisms of infection by TB 
 
During initial TB infection, Mtb bacilli are taken up by alveolar macrophages 
(and possibly dendritic cells (DCs)) in the lung alveoli.  The bacteria are not 
destroyed, due to the presence of thick waxy cell walls, but persist within the 
host cells and are transported to the draining lymph nodes.  There, a lesion 
develops with the attraction of monocytes; large numbers of CD4+ T cells 
accumulate.  A granuloma is formed through the induction of antigen-specific T 
cells; this eventually becomes surrounded by fibrosis, which can persist for 
many years, for as long as immunocompetence persists.  Interferon gamma 
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(IFN-γ) and tumour necrosis factor alpha (TNF-α) are important cytokines in this 
containment of infection (Kaufmann & McMichael, 2005). 
 
 
1.1.3 Opportunistic infections in HIV 
 
Infections associated with HIV-1 are the main causes of admission to hospitals 
and death in many African countries; most are caused by preventable and 
treatable infections such as Mtb, Salmonella, other enteric pathogens, bacterial 
pneumonia and malaria (Corbett et al., 2002). 
 
HIV-1 is known to interact with other diseases – as individuals become 
immunosuppressed, so opportunistic infections flourish.  In turn, HIV-1 
infectivity and clinical course can be altered by other infections (Figure 7) 
(Corbett et al., 2002). 
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Figure 7   
Potential interactions between HIV-1 and other infectious diseases. 
(reproduced from (Corbett et al., 2002)) 
STD: sexually-transmitted disease 
 
 
1.1.3.1 HIV-1 and TB coinfection 
 
TB is one of the most frequent serious HIV-1-associated infections, occurring as 
an early complication in 50-67% of the almost 40 million people world-wide 
living with HIV-1/AIDS (Ellner, 1990).  The majority of HIV-1/TB coinfected 
people live in sub-Saharan Africa.  Without proper treatment, approximately 
90% of those living with HIV-1 die within months of contracting TB; TB kills up to 
a half of all AIDS patients world-wide.  In comparison to the 10% of HIV-1/TB 
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coinfected individuals who develop active TB within a year, individuals infected 
with TB alone have a 10% lifelong risk of developing active TB (Kaufmann & 
McMichael, 2005). 
 
HIV-1 infection increases the risk of both reactivation of latent TB (Selwyn et al., 
1989), reinfection with Mtb (Small et al., 1993), and rapidly progressive newly 
acquired TB (Narain et al., 1992).  In fact, in a large cohort of South African 
miners, the risk of TB has been shown to double within a year of HIV-1 infection 
(Sonnenberg et al., 2005).  In turn, Mtb accelerates the progress of AIDS. 
 
Between 1990 and 2005, countries with a high adult HIV-1 prevalence (>4%) 
saw a far larger increase in TB incidence than countries with a lower HIV-1 
prevalence (Nunn et al., 2005).  This suggests that TB incidence is directly 
related to HIV-1 prevalence, as has been demonstrated for sub-Saharan African 
countries (Figure 8). 
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Figure 8   
Relationship between incidence of infectious TB and adult HIV-1 prevalence 
(2002). 
(reproduced from (Reid et al., 2006)) 
 
 
TB in the context of HIV-1 infection presents the following problems (according 
to the WHO; http://www.who.int/tb/hiv/faq/en/): 
• “TB is harder to diagnose in HIV-positive people.  
• TB progresses faster in HIV-infected people.  
• TB in HIV-positive people is almost certain to be fatal if undiagnosed or left 
untreated.  
• TB occurs earlier in the course of HIV-1 infection than many other 
opportunistic infections.” 
 
TB is the most common cause of death in HIV-1 positive Africans; at least 30% 
of HIV-1 positive Africans are coinfected with Mtb (Corbett et al., 2002, Corbett 
et al., 2003).  Incidence of TB is similar among patients infected with HIV-1 or 
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HIV-2 (adjusted for CD4 count), and mortality rates are similar in both groups 
(van der Sande et al., 2004).  In addition, HIV-1 coinfection with TB leads to 
increased risk of acquiring new secondary infections compared with HIV-1 
alone (Whalen et al., 1995). 
 
HIV-1 infection is facilitated in TB patients due to an increased expression of 
CXCR4 and CCR5 (Rosas-Taraco et al., 2006).  In addition, it has been shown 
in clinical (Martin et al., 1995, Wallis et al., 1993, Whalen et al., 1995) and in 
vitro (Shattock et al., 1994, Zhang et al., 1995) studies that infection with Mtb 
promotes the progression of HIV-1 disease.  Mycobacterial products are also 
known to induce cytokines such as TNF-α (Wallis et al., 1993), which may 
promote HIV-1 expression in latently infected cells (Folks et al., 1987). 
 
It has been shown, however, using combined data from several study cohorts in 
countries where TB treatment is widely available, that the progression of HIV-1 
is not necessarily inherently faster in individuals who develop TB when 
compared with other individuals with AIDS, of the same duration of HIV-1 
infection (Del Amo et al., 2003). 
 
Even though CD4+ T cell counts improve after HAART, Mtb-specific CD4+ T 
cells have a reduced capacity for IFN-γ secretion, as in cases of primary HIV-1 
infection (Sutherland et al., 2006).  Mtb infection has also been shown to modify 
T cell phenotype in HIV-1 infection, with markers such as CD3, CD45RA, 
CD45RO, and CD27 showing less decrease in coinfected patients, together 
with an increase in CD95 (Bernal-Fernandez et al., 2006). 
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In macaque monkeys infected with SIV, infection with BCG leads to the 
development of a tuberculosis-like disease within 4 months (Shen et al., 2002).  
In SIV-BCG coinfected macaques with clinically latent disease, BCG can be 
reactivated by bacterial superantigen challenge (independent of an increase in 
SIV viral load) (Shen et al., 2004).  This suggests that reactivation of latent TB 
in HIV-infected individuals may be partly due to further superinfection. The role 
of translocated microbial products (from the gastrointestinal tract) in the chronic 
activation of the immune system seen in HIV-1 infection is well-documented 
(Brenchley et al., 2006); this may have implications in the reactivation of latent 
TB. 
 
 
1.2 Immune abnormalities in HIV-1 and TB infection 
 
1.2.1 Basic immunology 
 
1.2.1.1 Innate immunity 
 
In mammals, the immune system comprises two arms, innate and acquired (or 
adaptive) immunity.  The innate immune system is the first line of defence 
against invading pathogens, governed primarily by constitutively expressed, 
germ-line encoded pattern recognition receptors (PRRs) on cells including 
phagocytes (such as macrophages and DCs) that recognise molecules 
characteristic of bacteria and viruses (known as pathogen-associated molecular 
patterns (PAMPs)).  Innate immune activation is non-specific, and targets 
neutrophils, monocytes/macrophages, DCs, natural killer cells (NKs) and 
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complement.  The best characterised of these receptors are the Toll-like 
receptors (TLRs); the role of cytoplasmic PRRs is less well understood but is 
critical to the immune response (Akira et al., 2006).   
 
On ligand binding by TLRs, signalling cascades lead to the selective 
transcriptional activation of genes involved in host defence, including 
proinflammatory cytokines and type 1 interferons (Akira et al., 2006).  
Macrophage killing of Mtb is evaded via the inhibition of IFN-γ-mediated 
signalling and hence the innate arm of the immune system (Akira et al., 2006). 
 
Innate immunity is critical in host defence in infants, since neonatal adaptive 
immune responses are naïve (Marodi, 2006).    
 
Adaptive immune responses are simultaneously initiated through the activation 
and maturation of DCs, which are professional antigen-presenting cells 
(Kabelitz & Medzhitov, 2007), thereby providing a link between the innate and 
adaptive immune responses.  
 
1.2.1.2 T-helper 1 and T-helper 2 cells 
 
T-helper (Th) cells can be divided into two subsets, Th1 and Th2.  Th1 
responses are characterised by IFN-γ and IL-2 production, and are associated 
with cell-mediated immunity; Th2 responses are characterised by production of 
IL-4, IL-5 and IL-13, and are associated with humoral immunity (Elliott et al., 
2004).  It has been proposed that a Th1 response, leading to macrophage 
activation, is required for protective immunity to TB, while a Th2 response, 
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which is expected to suppress type 1 responses, would be associated with 
susceptibility to TB (Elliott et al., 2004).  It has been postulated that a switch 
from Th1 to Th2 might be associated with the pathogenesis of HIV-1 (Clerici & 
Shearer, 1993), although this remains controversial.  While a study of healthy 
adolescents (both HIV-1 positive and HIV-1 negative) failed to detect shifts from 
Th1 to Th2 cytokine production early in disease (Becker, 2004), a phenotypic 
shift from Th1 to Th2 has been demonstrated at the single-cell level during the 
course of HIV-1 infection (Klein et al., 1997), and in HAART patients (with more 
advanced stages of disease), viremia and the presence of opportunistic 
infections were correlated with levels of cytokines characteristic of a Th2 
response in serum, and production by CD4+/CD8+ T cells  ex vivo (Sindhu et al., 
2006) 
 
 
1.2.2 The effect of HIV-1 on the immune system 
 
It was previously believed that HIV-1 caused depletion of CD4+ T cells slowly 
and progressively, eventually leading to AIDS.  However, it is now apparent that 
HIV-1 infection has an initial phase of extensive destruction of memory CD4+ T 
cells, particularly within the gut mucosa (Brenchley et al., 2006), followed by a 
phase of chronic immune activation and a gradual loss of remaining CD4+ T 
cells, in the slow and progressive stage of the disease (Mattapallil & Roederer, 
2006).  This loss of CD4+ T cells is correlated with markers of immune activation 
(Hazenberg et al., 2003). 
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In HIV-1 positive individuals, depletion of CD4+ T cells is associated with a 
decrease in production of type 1 and type 2 cytokines in response to 
mycobacterial antigens (Elliott et al., 2004). 
 
Immune abnormalities in HIV-1 infected patients include defects in the 
microbicidal responses of phagocytic cells, which could contribute to impaired 
defence against opportunistic pathogens (Meddows-Taylor et al., 2001a).  
Neutrophils from HIV-1 infected adults also show functional defects including 
phagocytosis (Lazzarin et al., 1986, Shalekoff et al., 1998), chemotaxis (Ellis et 
al., 1988, Meddows-Taylor et al., 1998, Valone et al., 1984), oxidative burst 
(Chen et al., 1993, Pitrak et al., 1993, Shalekoff et al., 1998), bacterial killing 
(Ellis et al., 1988, Murphy et al., 1988) and degranulation (Baley & Schacter, 
1985). 
 
Individuals coinfected with HIV-1 and Mtb show a greater impairment of 
polymorphonuclear leukocyte (PMNL) function to those infected with HIV-1 
alone (Baley & Schacter, 1985, Tiemessen et al., 2000b), consistent with the 
increased susceptibility to secondary infections found in HIV-1/TB coinfection 
compared to HIV-1 alone (Barin et al., 2006). 
 
Bentwich et al. (1998) suggest that the pathogenesis of AIDS, particularly in 
Africa, is at least partly due to chronic immune activation caused by other 
chronic infections, thereby increasing susceptibility to HIV-1 infection (Bentwich 
et al., 1998).  The same authors also propose that disease progression is 
influenced by the persistent stimulation of the immune system by HIV-1 
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infection itself, causing an “ageing-like process” in the functioning of the 
immune system.  During HIV-1 infection, the reduction in blood CD4+ T cell 
counts has been ascribed to both their redistribution to the lymphoid tissue, and 
to the attenuation of proliferation (Grundstrom & Andersson, 2006).  T cell 
activation, depending on the type of stimulus, leads to “full activation” 
(characterised by proliferation and often cell death), or to “partial activation” 
(resulting in selective expression of cellular functions and anergy to full 
activation).  Both forms of activation are induced in HIV-1 infection, explaining 
the functional defects in peripheral T cells in HIV-1 infection (Gougeon et al., 
1996).  
 
 
1.2.3 The effect of Mtb on the immune system 
 
In patients with active pulmonary TB, the immune activation of peripheral 
monocytes enhances susceptibility to HIV-1 infection in vitro; Mtb and its 
antigens can also upregulate in vitro HIV-1 replication (Wolday et al., 2005).  In 
Mtb infection (both in vitro and in vivo), human monocyte-derived macrophages, 
alveolar macrophages and CD4+ T cells show increased expression of CCR5 
and/or CXCR4, and their ligands (Wolday et al., 2005).  In the population 
groups we are studying, CXCR4 expression is reduced in patients with TB, HIV-
1, and dual  TB/HIV-1 infections (with TB exerting the greater effect), while 
CCR5 expression is increased (Shalekoff et al., 2001).  
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In HIV-1 with acute phase TB coinfection, plasma HIV-1 viremia is increased (at 
CD4 levels >500/µl) (Toossi et al., 2001) and mycobacteremia is frequently 
observed (Archibald et al., 1998).  In studies of African HIV-1/TB coinfected 
patients receiving anti-TB treatment, CD4+ T cell count does not increase, and 
plasma viral load remains high (Wolday et al., 2005).  In contrast, a study in 
Western patients showed TB treatment associated with a reduction in HIV-1 
viral load (Goletti et al., 1996), highlighting the importance of the choice of study 
cohort to exclude confounding factors, including genetic background. 
 
 
1.3 Chemokines and their receptors – a general overview 
 
1.3.1 Characteristics of chemokines 
 
Chemokines are chemotactic cytokines, which have the following 
characteristics: 
• They are small secreted protein molecules (8-17kDa) with potent 
chemotactic activity. 
• They are involved in organ development, angiogenesis, angiostasis, 
homeostatic leukocyte recirculation and immune regulation (Chensue, 
2001). 
• They mediate inflammatory processes including activation and chemotaxis 
of neutrophils, monocytes and lymphocytes to sites of infection (Miller & 
Krangel, 1992).   
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Cytokines themselves have the following characteristics (Alfano & Poli, 2002): 
• They act locally, although an overproduction can lead to systemic effects 
e.g. sepsis. 
• More than one can induce the same effect (redundancy). 
• The same cytokine can be produced by different cell types (pleiotropy). 
• A single cytokine/chemokine can interact with more than one receptor. 
 
The first chemokine to be cloned and characterised was interleukin-8 (IL-
8/CXCL8) (Matsushima et al., 1988); since then approximately 50 human 
chemokines have been identified using expressed sequence tag (EST) libraries 
(Chensue, 2001).   
 
Cytopathology of infected cells is probably the initial source of chemokines, 
which recruit and activate inflammatory leukocytes.  This activation leads to the 
induction of cytokines (e.g. IFN-γ and TNF-α), which in turn amplify chemokine 
synthesis.  The nett result is the destruction of infected cells, frequently 
associated with bystander damage. 
 
 
1.3.2 Classification of chemokines 
 
The chemokine superfamily is subclassified based on the arrangement of 
cysteine residues in the N-terminal region of the mature protein: C, CC (β-
chemokines), CXC and CXXXC (or CX3C) (Murphy et al., 2000), where C 
represents the N-terminal cysteine residues, and X the number of intervening 
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amino acids (Figure 9) (refer to Appendix B for a Table of chemokine 
nomenclature).   
 
 
 
 
Figure 9   
Chemokine structure. 
(from http://en.wikipedia.org/wiki/Chemokine) 
 
 
The CXC subfamily (which acts predominantly on neutrophils) is further 
classified, based on the presence or absence of a Glutamic acid-Leucine-
Arginine (ELR) triplet amino acid motif preceding the first of the N-terminal 
cysteine amino acids, into ELR and non-ELR types (angiogenic and angiostatic, 
respectively (Keane et al., 1998)).  CXC ELR+ chemokines (encoded on 
chromosome 4 in a multigene array) attract neutrophils to sites of inflammation, 
and induce the respiratory burst and granule exocytosis; production is 
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stimulated by, for example, IL-1, TNF-α or bacterial lipopolysaccharide (LPS) 
(Charo & Ransohoff, 2006).   
 
 
1.3.3 Characteristics of chemokine receptors 
 
Chemokine receptors are members of the guanosine nucleotide-protein-coupled 
receptors (GPCR) superfamily; they are 320-380 amino acids in length, with 
significant sequence homology.  Chemokine receptors have seven 
transmembrane hydrophobic domains with three intracellular and three 
extracellular hydrophilic loops; the extracellular amino-terminal region is 
involved in chemokine binding; the intracellular carboxy-terminal region is 
involved in G-protein linking and regulation (Chensue, 2001).   
 
Chemokine (and chemokine receptor) genes are, for the most part, clustered 
within four distinct regions of the genome (Clark & Dean, 2004): 
CC   17q11-21 
CXC   4q12-21 
CCR and CXCR 3p21-24 
CXCR   2q21-35 
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1.4 Chemokines and chemokine receptors important in HIV-1 and TB 
infection  
 
1.4.1 General background 
 
HIV-1 expression in latently infected cells can be upregulated by pro-
inflammatory cytokines (including IL-1 (Poli et al., 1994), IL-6 (Poli et al., 1990, 
Poli et al., 1994), TNF-α and TNF-β (Folks et al., 1989, Matsuyama et al., 
1989), and GM-CSF (Folks et al., 1987)); immunosuppressive cytokines (IL-4 
(Schuitemaker et al., 1992) and TGF-β (Poli et al., 1991)) inhibit HIV-1 
expression (Table 1) (refer to Appendix C for a Table of cytokines involved in 
HIV infection). 
 
 
Table 1   
Cytokine effects on driving HIV-1 latency and replication. 
(reproduced from (Alfano & Poli, 2002)) 
 
Latency LIF, IFN-α/β, IL-1, IL-13, IL-16, RANTES, MIP-1α/β, MDC 
Replication TNF-α/β, CD30L, M-CSF, GM-CSF, IL-1α/β, IL-3, IL-6, IL-7, IL-
8, MCP-1 
Latency/replication 
(depending on other factors) 
TGF-β, IFN-γ, IL-2, IL-4, IL-10, IL-12, IL-15 
 
 
In TB, HIV-1, and TB/HIV-1 coinfection, Th1 responses to both TB and HIV-1 
specific antigens are generated, but still disease progresses, leading to the 
theory that a “subversive Th2 component” undermines the Th1 response and 
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therefore causes pathogenesis (Dheda et al., 2005).  Th2 cytokines seem to 
play a role in HIV-1/TB coinfection, but not in HIV-1 alone (Dheda et al., 2005). 
 
CC chemokines (or β-chemokines) are best studied for their central role in HIV-
1 infection, as CCL3, CCL4 and CCL5 are the natural ligands for the HIV-1 
coreceptor CCR5.  In vitro, CC chemokines can block replication of R5 HIV-1 
strains (Cocchi et al., 1995).  They are also involved in the regulation of cell-
mediated immunity (Matsukawa et al., 2000).   
 
Pulmonary TB, with or without concomitant HIV-1 infection, is associated with 
higher levels of CXCL12 (Shalekoff & Tiemessen, 2003b).  IL-7 levels, on the 
other hand, are increased in HIV-1 infection, with or without concomitant 
pulmonary TB (Shalekoff & Tiemessen, 2003b). 
 
 
1.4.2 CCL3 and other CC chemokines 
 
CCL3 (previously known as macrophage inflammatory protein (MIP)-1α) is a CC 
chemokine produced during inflammation as part of the innate immune 
response.  CCL3 (with CCL4) is produced by epithelial cells, lymphocytes and 
platelets, and is a chemoattractant for monocytes, NK cells, eosinophils and 
DCs (Lillard et al., 2003).  In studies on mice, the development of humoral and 
cellular mucosal and systemic immunity is enhanced by CCL3 and CCL4; CCL3 
drives both Th1 and Th2 responses, while CCL4 is limited to Th2 (Lillard et al., 
2003). 
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Through interaction with its receptors (CCR1 and CCR5), CCL3 helps mediate 
the local accumulation of leukocytes.  Deletion of the CCL3 gene in mice 
(present in single allelic form) has no apparent effect on development, but has a 
profound effect on immunological responses in a variety of disease models 
(Cook et al., 1995).   
 
1.4.2.1 CC chemokines and HIV-1 
 
During HIV-1 infection, intracellular levels of the CC chemokines CCL3 and 
CCL4 tend to be increased in lymphocytes, with a corresponding decrease in 
their secretion into lymphocyte culture supernatants (Jennes et al., 2004).  In 
contrast, in HIV-1 patients CCL5 tends to be increased both intracellularly and 
in culture supernatants (Jennes et al., 2004).  After more than 3 years of 
HAART, intracellular levels of CCL4 and CCL5, and CCL3 and CCL4 in 
supernatant, reach normal levels, coincident with higher CD4+ T cell counts 
(Jennes et al., 2004). 
 
In the population groups under investigation in this study, stimulated cultures of 
cord-blood mononuclear cells (CBMCs) from infants born to HIV-1 positive 
mothers show an increase in CCL3 and CCL4 production compared to those 
born to HIV-1 negative mothers; a deficiency in this stimulated CCL3 production 
(seen in both infants and mothers) is associated with susceptibility to 
intrapartum mother-to-child transmission (MTCT) of HIV-1 infection (Meddows-
Taylor et al., 2006).  This suggests an important role for this particular 
chemokine in protection from infection. 
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Disease progression in HIV-1 infection is less rapid in individuals showing high 
levels of CC chemokine production by phytohaemagglutinin (PHA)-stimulated 
peripheral blood mononuclear cells (PBMCs) (Ullum et al., 1998), while CD8+ T 
cells from asymptomatic HIV-1 infected individuals produce higher levels of 
CCL3 and CCL4 upon PHA stimulation, in comparison with those from AIDS 
patients (Cocchi et al., 2000).  In HIV-1 uninfected haemophiliacs repeatedly 
exposed to HIV-1-contaminated clotting Factor VIII, PHA-activated PBMCs 
show an overproduction of CC chemokines (Zagury et al., 1998).  In HIV-1 
infected long-term non-progressors (LTNPs), enhanced production of CC 
chemokines, as a result of vigorous HIV-1-specific CD4+ T cell proliferative 
responses, is associated with control of viremia (Rosenberg et al., 1997). 
 
In addition, CC chemokines have been associated with protective immunity in 
animal models.  In rhesus macaques vaccinated against SIV, the production of 
CC chemokines (specifically CCL4 and CCL5) by CD8+ T cells is associated 
with protective immunity (Lehner et al., 1996), while CC chemokine production 
correlates with protection against infection by SIV in both naïve and vaccinated 
macaques (Ahmed et al., 2005). 
 
It has been shown, however, that expression of CCL3, CCL4 and CCL5 is very 
high in the peripheral lymph nodes of patients during early acute HIV-1 infection 
(Nilsson et al., 2007).  This suggests that during the dissemination of HIV-1 
infection, viral replication may not necessarily be suppressed by CC 
chemokines, which highlights the complex interplay of innate immunity. 
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1.4.3 CCR5 and CXCR4: HIV-1 entry coreceptors 
 
Along with CD4, the chemokine receptors CCR5 and CXCR4 are coreceptors 
for HIV-1 entry into CD4+ T cells.  CXCR4 is utilized by T cell tropic or X4 HIV-1 
strains (previously known as syncitia-inducing, or SI), CCR5 by macrophage-
tropic or R5 strains (previously known as non-syncitia-inducing, or NSI).  HIV-1 
strains utilizing both receptors are termed dual-tropic, or R5X4.  R5 strains are 
considered to be primarily responsible for disease transmission, as they are 
generally the virus strains recovered following seroconversion, while X4 strains 
are found preferentially during late-stage disease (Amara et al., 1997).  
However, exceptions can occur, as demonstrated by the fact that individuals 
homozygous for mutations resulting in a complete lack of cell-surface CCR5 
can still be infected (although rarely) with X4 or R5X4 dual-tropic HIV-1 strains 
(Gray et al., 2006). 
 
The specific ligands for CCR5 are MIP-1α/CCL3, MIP-1β/CCL4 and 
RANTES/CCL5 (Cocchi et al., 1995); additional agonists for CCR5 are CCL7 
and CCL14 (high affinity) and CCL13 (weak affinity), while CCL8 is a natural 
antagonist (Amara et al., 1997).  To date, the only ligand known for CXCR4 is 
SDF-1α/CXCL12 (Amara et al., 1997).   
 
CCL3, CCL4 and CCL5 are all inhibitors of HIV-1 binding – in fact, clinical trials 
are currently underway to investigate the use of chemokine receptor-directed 
agents as HIV-entry blockers (Mills & DeMartino, 2004).  Maraviroc is the first 
CCR5 antagonist to receive FDA approval, granted in August 2007, and 
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European Commission approval, granted in September 2007.  The inhibitory 
effects of chemokines are only partly due to steric hindrance through the 
blocking of their receptor CCR5; also important is the desensitisation and 
internalisation of CCR5 through ligand binding.  The most significant factor 
might be the complex interaction of immune system components in cytokine-
induced immune cell recruitment and regulation, including (but not limited to) 
the development of Th1 and Th2 responses.  A further, recently-described 
effect of CCL3 binding to CCR5 on CD4+ T cells and DCs is to increase the de 
novo synthesis of APOBEC3G (Pido-Lopez et al., 2007), which is a potent post-
entry inhibitor of HIV-1 infectivity. 
 
In most infected individuals in Europe/USA, CD4 depletion is associated with a 
mutational shift in HIV-1 env coreceptor preference from CCR5 to CXCR4 (“R5 
to X4 tropism”) (O'Brien & Nelson, 2004).  The emergence of X4 and/or R5X4 
viruses is associated with the acceleration of CD4+ T cell depletion and disease 
progression (Kaleebu et al., 2007, Philpott, 2003). 
 
In Mtb infection of macrophages, surface expression of CXCR4 is raised, and 
the chemokines CCL4, CCL5 and CX3CL1 are upregulated.  This would be 
permissive for replication of X4 viruses, while inhibiting R5 viruses, providing a 
further possible mechanism for the acceleration of AIDS by TB coinfection 
(Hoshino et al., 2004).  
 
CCR5 is more abundant on the surface of Th1 cells; CXCR4 is upregulated by 
IL-4, so linked to Th2 differentiation (Alfano & Poli, 2001).  This implies that 
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CCR5, linked with the Th1 type immune response, may be associated with 
control of TB infection; CXCR4, linked with the Th2 type of immune response, 
may be associated with susceptibility to TB, while at the same time contributing 
to the switch from R5 to X4 strains of HIV-1 and hence progression to AIDS. 
 
Contrasting results show that there is a significant reduction in the proportion of 
leukocytes expressing CXCR4 in patients infected with HIV-1 and/or TB, with 
TB having the most dramatic effect (Shalekoff et al., 2001).  Correspondingly, 
there is an increase in the proportion of CCR5-expressing leukocytes; this could 
have the direct effect of increasing viral entry of R5 HIV-1 strains (Shalekoff et 
al., 2001).   
 
1.4.3.1 Polymorphisms in coreceptors influence 
susceptibility to HIV-1  
 
A 32-bp deletion within the CCR5 gene results in a truncated protein which is 
not expressed at the cell surface, but is retained within the endoplasmic 
reticulum and rapidly degraded; individuals homozygous for this mutation are 
highly resistant to HIV-1 infection (Liu et al., 1996, Samson et al., 1996).  Two 
mechanisms seem to be involved in this resistance: the loss of surface CCR5 
expression, and the scavenging of CXCR4 (Agrawal et al., 2004).  Individuals 
heterozygous for CCR5 ∆32/wt, when compared to CCR5 wt/wt individuals, 
show a lower cell-surface expression of CCR5 (and lower levels of circulating 
CXCL12), with a concomitant increase in CXCR4 expression (Shalekoff & 
Tiemessen, 2003a).  There are other CCR5 mutations that affect the coding 
sequence and the promoter, most of which are relatively rare, and some of 
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which can affect ligand binding and HIV-1 disease progression (reviewed in 
(Amara et al., 1997)). 
 
 
1.4.4 CXCL8 
 
CXCL8 (previously known as IL-8) is an 8-kDa polypeptide; it is a CXC 
chemokine, in the ELR+ group, important in the inflammatory process as part of 
the innate immune response.  It is a potent chemoattractant for the recruitment 
of leukocytes to inflammatory sites (Pace et al., 1999); however, in recruiting 
neutrophils, it can cause significant bystander damage (Chensue, 2001).  
CXCL8 also activates monocytes (Charo & Ransohoff, 2006) and neutrophils, 
the response of which includes respiratory burst induction and chemotaxis 
(Matsushima & Oppenheim, 1989), lysosomal enzyme release and enhanced 
killing of microorganisms (including Mtb) (Liles & Van Voorhis, 1995).  CXCL8 
production is stimulated by a wide variety of microorganisms, including bacteria, 
mycoplasma, mycobacteria, protozoa, helminths and viruses (Chensue, 2001).  
It is produced predominantly by monocytes/macrophages (Yoshimura et al., 
1987), but also by stimulated human blood mononuclear leukocytes (Yoshimura 
et al., 1987), T lymphocytes, endothelial cells, keratinocytes, fibroblasts (Liles & 
Van Voorhis, 1995), and polymorphonuclear neutrophils (Cassatella et al., 
1992). 
 
 
 
 30 
1.4.4.1 CXCL8 and TB 
 
The role of CXCL8 in TB has become of great interest, as elevated levels of 
CXCL8 are found in tuberculous pleural exudate, bronchoalveolar lavage fluid 
and cerebrospinal fluid (Mastroianni et al., 1994).  High levels of CXCL8 are 
expressed in tuberculous granulomas heavily infiltrated by neutrophils, and 
plasma CXCL8 concentrations are higher in fatal cases of TB compared to 
survivors (Friedland et al., 1995).  CXCL8 is up-regulated in macrophages as 
part of the macrophage activation program in response to Mtb infection, and 
sputum levels are reduced in parallel to Mtb in response to anti-TB treatments 
(Ribeiro-Rodrigues et al., 2002).  CXCL8 has been shown to reduce the survival 
of Mtb within macrophages, while inhibition of CXCL8 is associated with 
proliferation of intracellular Mtb (O'Kane et al., 2007).  In rabbits, anti-CXCL8 
antibodies inhibit granuloma formation, suggesting that CXCL8 may be 
essential for host defence to Mtb (Larsen et al., 1995).  Resting PBMC 
production of CXCL8 is lowered in extrapulmonary TB (in HIV-negative patients) 
compared to controls (Sterling et al., 2001).  In addition, fibroblasts in culture 
are strongly stimulated to produce CXCL8 in response to conditioned medium 
from Mtb-infected monocytes (O'Kane et al., 2007). 
 
Furthermore, latent Mtb infection can be distinguished from active disease by 
gene expression of CXCL8 in activated PBMCs (raised in latent vs. active TB), 
together with forkhead box P3 (FOXP3) (raised in active TB only) and IL-12β 
(raised in latent vs. active TB) (Wu et al., 2007). 
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1.4.4.2 CXCL8 and HIV-1 or HIV-1/TB 
 
CXCL8 levels are upregulated in both serum (Matsumoto et al., 1993) and 
plasma (Thea et al., 1996) of HIV-1 infected adults, although not in HIV-1 
infected children (Meddows-Taylor et al., 2001b).  Circulating levels of CXCL8 
are also significantly raised in HIV-1 patients with pulmonary TB, but not in 
patients with TB alone (Meddows-Taylor et al., 1999a).  CXCL8 suppresses 
HIV-1 replication in naturally-infected CD4+ T cells (Mackewicz et al., 1994) and 
in promonocytic U1 cells as a model of HIV-1 latency (Tiemessen et al., 2000a).  
However, CXCL8 can either decrease or increase HIV-1 replication on induction 
by proinflammatory cytokines, depending on the nature of the cytokine and 
CXCL8 concentration (Tiemessen et al., 2000a).  HIV-1 replication in 
macrophages and T lymphocytes is stimulated by CXCL8, while levels of 
CXCL8 in lymphoid tissue are increased in AIDS patients (Lane et al., 2001).  
U1 cells (with latent HIV-1 infection) show an increase in spontaneous secretion 
of CXCL8, but a reduced ability to secrete CXCL8 in response to cytokines 
(Tiemessen & Martin, 2000). 
 
1.4.4.3 CXCR1 and CXCR2 
 
There are two types of CXCL8 receptor, CXCR1 and CXCR2.  These are found 
on all PMNLs, monocytes, and 5-25% of total lymphocytes, with CXCR2 
dominant on monocytes and lymphocytes (Chuntharapai et al., 1994).  Of the 
CXCR positive lymphocytes, 7-42% are CD8+ T cells, and 39-76% are CD56+ 
NK cells (Chuntharapai et al., 1994).  Both receptors mediate chemotaxis, 
granule enzyme release, and cytosolic Ca2+ changes, although only CXCR1 
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triggers the respiratory burst (Jones et al., 1996).  Surface expression of both 
receptors is down-regulated on PMNLs from HIV-1 infected patients, and in 
patients coinfected with HIV-1 and Mtb (Meddows-Taylor et al., 1998), relating 
to impaired CXCL8-induced degranulation (Meddows-Taylor et al., 1999b).  
These decreases are independent of the patients immunologic status 
(Meddows-Taylor et al., 1998).  Children infected vertically with HIV-1 have 
significantly altered expression of CXCR2, but not CXCR1, compared to HIV-1 
uninfected children; CXCR2 is significantly reduced in HIV-1 infected children 
with severe disease (Meddows-Taylor et al., 2001a).  In HIV-1 exposed-
uninfected infants, CXCR1 and CXCR2 expression decreases with age from 12 
months, as does the proportion of PMNLs expressing the receptors (Meddows-
Taylor & Tiemessen, 2004). 
 
CXCL8 is known to regulate its own receptor expression – receptor expression 
is down-regulated in response to CXCL8, but the down-regulated receptor can 
be rapidly recycled to the neutrophil cell surface (Samanta et al., 1990).  This 
suggests that the down-regulation of CXCL8 receptors seen in HIV-1, and in 
coinfection with HIV-1 and TB, may be modulated by the up-regulation of 
CXCL8 itself, or alternatively by altered recycling of the receptors (Meddows-
Taylor et al., 1998). 
 
Dysregulation of CXCL8 (and its receptors) in HIV-1 infection could alter cell 
trafficking, which could significantly alter the role of neutrophils in bacterial 
coinfections, and in HIV-1 dissemination by altered trafficking of T lymphocytes 
(Tiemessen & Martin, 2000). 
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Chemokine receptors can also cross-regulate the functions of each other (Ali et 
al., 1999, Richardson et al., 2000).  CXCL8 activation of CXCR1 (but not 
CXCR2) has been shown to cause the cross-phosphorylation and 
desensitisation of both CCR5 and CXCR4 (Richardson et al., 2003).  However, 
CXCR1 activation leads to the internalisation of CCR5 but not CXCR4, and can 
thus inhibit HIV-1 infection using CCR5 only (Richardson et al., 2003). 
 
 
1.5 Genetics of resistance / disease progression 
 
The fact that host genetic factors play a major role in susceptibility to HIV-1 
infection is suggested firstly by the occurrence of uninfected individuals 
engaged in high-risk behaviour, and uninfected infants born to HIV-1-infected 
mothers (“exposed uninfected”) and secondly by differing immunological 
responses to infection (Shrestha et al., 2006). 
 
The importance of genetic factors in HIV-1 and AIDS is also inferred by the time 
of progression from HIV-1 infection to AIDS-defining illnesses – while median 
time to AIDS-defining pathologies is 10 years, rapid progressors can develop 
AIDS within 1-5 years (Figure 10).  “Long-term non-progressors”, in contrast, 
can remain healthy for up to 20 years, while “elite controllers” are known to 
maintain viral loads at undetectable levels (< 50 copies per ml) for many years, 
even in the absence of antiretroviral therapy.  These “HIV-1 controllers” show 
potent constitutive anti-HIV-1 activity by CD8+ T cells (Saez-Cirion et al., 2007). 
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Figure 10   
A generalized graph of the relationship between HIV-1 copies (viral load) and 
CD4 counts over the average course of untreated HIV-1 infection. 
Any particular individual's disease course may vary considerably. 
 CD4+ T cell count (cells per µl) 
 HIV-1 RNA copies per ml of plasma 
(from http://en.wikipedia.org/wiki/Hiv) 
 
 
It has been pointed out that the more genetic factors that are identified as being 
associated with high-risk for HIV-1 and AIDS, the “closer we come to giving 
patients a virtual death sentence” (Griffiths, 2005), due to insufficient potent and 
specific antiretroviral drugs.  However, any advances in our understanding of 
both susceptibility to HIV-1 infection and progression to AIDS can only assist in 
the identification of new drug targets and possibly prevention strategies, so 
should be actively pursued. 
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Statistics based on the mutual information between disease and causative 
factors (the “explained fraction”) can be used to estimate the contribution of 
known genetic factors to epidemiological data (Nelson & O'Brien, 2006).  
Nelson and O’Brien (Nelson & O'Brien, 2006) have shown that 9% of slow 
progression to AIDS can be explained cumulatively by 13 genetic factors 
(polymorphisms in CCR5, CCR2, SDF-1, IL10 and RANTES, HLA-B and KIR-
3DS1 alleles, and combinations of these).  They suggest that more host genetic 
factors yet to be discovered may further explain AIDS progression. 
 
Appendix D provides a summary of genes involved in resistance to HIV-1 and 
TB.  Genetic determinants of resistance to both HIV-1 and TB are well 
documented, but vary depending on the population studied.  Given our focus on 
certain chemokine molecules, namely CCL3 and CXCL8, these are discussed 
in more detail below. 
 
 
1.5.1 Genetics of CCL3 
 
In humans, the CCL31 protein is encoded by two functional genes, CCL3 
(present at 2 copies per diploid genome) and CCL3L1 (present at variable copy 
number) (Irving et al., 1990, Nakao et al., 1990) (Figure 11).  Although CCL3 
and CCL3L1 share 94% nucleotide sequence similarity (refer to Appendix E for 
genomic DNA sequences), CCL3L1 encodes a biologically distinct protein that 
                                            
1
 “CCL3” denotes the combined protein products of both the CCL3 and CCL3L1 genes, unless 
otherwise specified. 
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binds CCR3 in addition to CCR5, and is a more potent agonist of CCR5.  The 
CCL3L1 protein, unlike CCL3, can be cleaved by CD26 (a membrane-
associated serine protease dipeptidyl peptidase) to generate a –2 variant that 
has even higher affinity for CCR1 and CCR5 (Proost et al., 2000), making it the 
most potent known inhibitor of HIV-1 entry by a factor of 30 (Menten et al., 
2002). 
 
 
Introns
Alu
86 66 4197 115 88688 420
Untranslated regions
Translated leader sequences Translated protein sequences
86 69 4207 115 88685 420
Exon 1 Exon 2 Exon 3
314
 
 
Figure 11   
CCL3 and CCL3L1 gene structure. 
(adapted from (Nakao et al., 1990) and (Menten et al., 2002)) 
 
 
An increase in CCL3L1 copy number is associated with increased CCL3 protein 
production (Townson et al., 2002), and is negatively associated with the 
proportion of CD4+ T cells expressing CCR5 (Gonzalez et al., 2005).  CCL3L1 
copy number less than the population specific average is strongly associated 
with HIV-1/AIDS susceptibility (Gonzalez et al., 2005).  It is therefore clear that 
the study of the genetics of CCL3 production and the associated phenotypes 
will contribute greatly to an understanding of susceptibility to HIV-1 infection 
within our study populations. 
CCL3 
CCL3L1 
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The CCL3/CCL3L1 genes (also known as LD78α and LD78β) are clustered on 
chromosome 17q11.2 with other CC chemokine genes, including CCL4/CCL4L1 
(Naruse et al., 1996, Nomiyama et al., 2001).  In addition, there is a non-
functional pseudogene (LD78γ), which is truncated at the 5’ end and therefore 
not expressed. 
 
It is likely that gene duplication (estimated to have occurred 10 million years ago 
(Nakao et al., 1990)) generated the ancestral forms of CCL3, CCL3L1, CCL4 
and CCL4L1, which were then preserved due to the evolution of distinct 
biological function; the variable copy number of CCL3L1 (and CCL4L1) is 
probably due to an association with a repeat unit which is highly susceptible to 
duplication, although CCL3L1 and CCL4L1 appear to duplicate independently 
(Shao et al., 2007).  
 
Median CCL3L1 gene copy number differs in different population groups 
(Gonzalez et al., 2005), leading to the hypothesis that gene dose relative to the 
average in each population group influences HIV/AIDS susceptibility, rather 
than copy number per se.  Low CCL3L1 copy number is a major determinant of 
enhanced HIV-1 susceptibility in both mother-to-child and adult-to-adult 
infection (Gonzalez et al., 2005).  In addition, in HIV-1 infected adults, lower 
CCL3L1 gene copy numbers have been shown to be associated with an 
increased risk of rapid progression to AIDS or death (Gonzalez et al., 2005). 
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Many copy number polymorphisms (CNPs) contribute to human genetic 
diversity (Sebat et al., 2004) – representational oligonucleotide microarray 
analysis (ROMA) of 20 healthy individuals showed CNPs widely distributed 
throughout the genome, comprising 70 genes within a total of 221 CNPs.  This 
is perhaps not surprising, since it seems that copying, duplication and 
multiplication processes are important in the evolution of protein families, and 
that new gene functions evolve by exploiting pre-existing genes (Britten, 2005). 
 
Other genes which have been shown to be present in variable copy can result 
in distinct phenotypes – e.g. Fcgr3, in which a low copy number of the FCGR3B 
gene is linked to susceptibility to immunologically mediated glomerulonephritis 
(Aitman et al., 2006). 
 
 
1.5.2 Genetics of CXCL8 
 
A common single nucleotide polymorphism (SNP), located 251 base pairs (bp) 
upstream of the IL8 transcription start site (refer to Appendix E for genomic 
DNA sequences), has been shown to be associated with changes in CXCL8 
production by LPS-stimulated whole blood (Hull et al., 2000).  The IL8-251A 
allele (associated with increased CXCL8 production) is significantly related to 
greater severity of respiratory syncytial virus (RSV) bronchiolitis (Hull et al., 
2000), although IL8-251A may not be the functional allele itself, but may lie in 
linkage disequilibrium with the functional variant (Hull et al., 2001).  Another 
study has shown a significant association between the IL8-251A allele and TB 
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susceptibility (Ma et al., 2003). Interestingly, the IL8-251T→A SNP is located 
upstream of the promoter binding sites for transcription factors (Ma et al., 2003), 
which raises the question of how its effects are exerted.  It has been suggested 
that if CXCL8 expression was increased, an excess of leukocytes may be 
attracted to the site of Mtb infection, causing extensive tissue damage and 
increasing the risk of clinical TB (Ma et al., 2003). 
 
 
1.6 Aims of study 
 
This study addressed the production of a group of chemokines (CCL3, CCL4, 
CCL5, CXCL8 and CXCL12) that are known to play an important role in the 
pathogenesis of either HIV-1 or TB.  These were evaluated in the context of 
single infections (HIV-1 and TB groups) and of coinfection with both organisms 
(HIV-1/TB group).  Circulating levels of chemokines and the ex vivo cellular 
ability to produce these chemokines were monitored.   
 
Altered production profiles of two chemokines, CCL3 and CXCL8, have been 
associated with MTCT of HIV-1 (Meddows-Taylor et al., 2006) and adult TB (Ma 
et al., 2003), respectively.  We hypothesised that a known genetic determinant 
of altered CCL3 production (CCL3L1 gene copy number (Townson et al., 2002)) 
would be associated with maternal-infant HIV-1 transmission, and that a genetic 
polymorphism (IL8-251T→A), associated with enhanced CXCL8 production 
(Hull et al., 2000) and susceptibility to TB in African Americans (Ma et al., 
2003), would be highly represented in the South African Black population. 
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Specific objectives 
 
1. To evaluate circulating chemokine levels (CCL3, CCL4, CCL5, CXCL8 
and CXCL12) in the presence of HIV-1 infection, pulmonary TB, and 
coinfection with HIV-1 and Mtb.   
 
2. To monitor unstimulated and PHA-stimulated PBMC capacity to produce 
CCL3, CCL4, CCL5, CXCL8 and CXCL12, in groups divided as above. 
 
3. To establish methodologies for determining the presence of genetic 
determinants that may affect CCL3 (CCL3L1 gene copy number) and 
CXCL8 (IL8-251T→A SNP) production phenotypes, and to relate these 
genetic polymorphisms to circulating levels of CCL3 and CXCL8. 
 
4. To examine CCL3L1 gene copy numbers within South African population 
groups, and within the context of MTCT of HIV-1. 
 
5. To determine the distribution of the IL8-251T→A SNP within South 
African population groups, and to investigate this polymorphism in the 
context of pulmonary TB. 
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CHAPTER 2 
 
MATERIALS AND METHODS 
 
 
2.1 Study cohorts 
 
2.1.1 HIV-TB cohorts 
 
Samples from two separate “HIV-TB” cohorts were utilised in this study. 
 
Characteristics of the first cohort of individuals (HIV-TB coh1), all from the 
Johannesburg area and grouped as control (HIV-1 and TB negative), HIV-1 
(HIV-1 positive, TB negative), TB (HIV-1 negative, TB positive) and HIV-1/TB 
(HIV-1 positive, TB positive) groups are shown in Table 2.  Some analyses 
(Chapter 3) were restricted to Black antiretroviral-naïve individuals within these 
cohorts.  Characteristics of these individuals are therefore presented separately 
in Table 3. 
 
Plasma and DNA samples from HIV-TB coh1 were used for quantitating 
chemokine levels (Chapter 3.3.1), and for determining CCL3L1 gene copy 
number (Chapter 4), respectively.  DNA samples from the TB groups (TB and 
HIV-1/TB) were in addition used for the IL8-251T→A polymorphism study 
(Chapter 5). 
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Table 2   
Characteristics of HIV-TB coh1. 
 
Grouping 
Control 
n=82 
HIV-1 
n=48 
TB 
n=28 
HIV-1/TB 
n=62 
Gender  (n (%)) 
Male  
Female  
Unknown  
 
49 (60) 
32 (39) 
1 (1) 
 
28 (58) 
20 (42) 
0 (0) 
 
12 (43) 
16 (57) 
0 (0) 
 
19 (31) 
40 (65) 
3 (5) 
Population group  (n (%)) 
Black 
Caucasian 
Asian 
Mixed 
Unknown 
 
49 (60) 
30 (37) 
2 (2) 
0 (0) 
1 (1) 
 
26 (54) 
19 (40) 
1 (2) 
2 (4) 
0 (0) 
 
28 (100) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
 
62 (100) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
Age  (years) 
Mean ± sd 
Range 
 
44±11 
24-65 
 
36±8 
24-59 
 
36±13 
18-66 
 
34±9 
22-56 
HIV-1 disease status  (n (%)) 
Asymptomatic 
AIDS 
Unknown 
 
Not relevant 
 
26 (54) 
13 (27) 
9 (19) 
 
Not relevant 
 
0 (0) 
62 (62) 
0 (0) 
Antiretroviral therapy  (n (%)) 
ARV + 
ARV - 
 
Not relevant 
 
19 (40) 
29 (60) 
 
Not relevant 
 
0 (0) 
62 (100) 
Antituberculosis therapy  (n (%)) 
Anti-TB + 
Anti-TB - 
Unknown 
 
Not relevant 
 
Not relevant 
 
24 (86) 
2 (7) 
2 (7) 
 
59 (95) 
0 (0) 
3 (5) 
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Table 3   
Characteristics of Black, antiretroviral-naïve individuals HIV-TB coh1. 
 
Grouping 
Control 
n=49 
HIV-1 
n=17 
TB 
n=28 
HIV-1/TB 
n=62 
Gender  (n (%)) 
Male  
Female  
Unknown  
 
40 (82) 
9 (18) 
0 (0) 
 
6 (35) 
11 (65) 
0 (0) 
 
12 (43) 
16 (57) 
1 (0) 
 
19 (31) 
40 (65) 
3 (5) 
Age  (years) 
Mean ± sd 
Range 
 
43±11 
24-65 
 
30±6 
24-50 
 
36±13 
18-66 
 
34±9 
22-56 
HIV-1 disease status  (n (%)) 
Asymptomatic 
AIDS 
Unknown 
 
Not relevant 
 
9 (53) 
3 (18) 
5 (29) 
 
Not relevant 
 
0 (0) 
62 (62) 
0 (0) 
Antituberculosis therapy  (n (%)) 
Anti-TB + 
Anti-TB - 
Unknown 
 
Not relevant 
 
Not relevant 
 
24 (86) 
2 (7) 
2 (7) 
 
59 (95) 
0 (0) 
3 (5) 
 
 
 
The second “HIV-TB” cohort (HIV-TB coh2) consisted of Black individuals from 
Johannesburg hospitals with groupings as above (16 of each of normal donor, 
HIV-1 positive, TB positive and HIV-1/TB coinfected individuals).  All TB and 
HIV-1/TB patients were receiving standard anti-TB therapy; none of the HIV-1 
infected individuals were receiving antiretroviral therapy (ART) (Meddows-
Taylor et al., 1999a).  PBMCs were previously isolated from these individuals 
and cultured as described by Meddows-Taylor et al. (Meddows-Taylor et al., 
1999a).  The stored supernatants were used for comparisons of levels of 
chemokines by ELISA (Chapter 3.3.2). 
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2.1.2 MTCT cohort 
 
MTCT samples consisted of blood samples collected from Black HIV-1 infected 
(n=267) and uninfected (n=13) mothers, and infants born to HIV-1 infected 
mothers (n=207; remaining were lost to follow-up).  Samples were drawn from 3 
separate mother-infant groups which formed part of prevention of mother-to-
child transmission (PMTCT) studies (Table 4):  Group 1 from Chris Hani 
Baragwanath Hospital (96 mothers received single-dose nevirapine (NVP); 98 
mothers had no antenatal ART) (Gray et al., 2005, Kuhn et al., 2007); Group 2 
from Coronation Hospital (all mothers received single-dose NVP except for 3 
who received triple-drug therapy) (Kuhn et al., 2007); and Group 3, also from 
Chris Hani Baragwanath Hospital (mothers received one of 3 ART regimens of 
zidovudine and lamivudine) (Team, 2002). 
 
Blood samples were collected into EDTA Vacutainers (Becton Dickinson, San 
Jose, California, USA; refer to Appendix F for a full list of suppliers); peripheral 
blood samples were collected from all mothers, while blood samples were 
collected from infants (at birth, 6 weeks and 3 months) born to the HIV-1 
infected mothers.  Infant samples were divided into groups as follows: exposed-
uninfected (EU) (HIV-1 DNA PCR negative at birth and at 6 weeks); HIV-1 
infected in utero (IU) (HIV-1 DNA PCR positive at birth and at 6 weeks); and 
HIV-1 infected intrapartum (IP) (HIV-1 DNA PCR negative at birth but positive at 
6 weeks).     
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Table 4   
Maternal and infant samples from the MTCT cohort. 
 
Infants 
Group Mothers Infected  
in utero 
Infected 
intrapartum 
Infected 
(timing 
unknown) 
Exposed 
uninfected Total 
1 194 6 14 44 69 133 
2 42 - - 7 36 43 
3 31 - - 8 23 31 
Total 267 6 14 59 128 207 
 
 
 
DNA was extracted from stored cell pellets/whole blood from the MTCT cohort 
and used for determining CCL3L1 gene copy number (Chapter 4.3.3) and the 
presence of the IL8-251T→A polymorphism (HIV-1 positive mothers only; 
Chapter 5.4.4). 
 
 
2.1.3 Eskom study cohort 
 
DNA samples from the Eskom study cohort (part of an HIV-1 prevalence study 
among Eskom staff members) were used for the population-based study of 
CCL3L1 gene copy numbers, and for the IL8-251T→A polymorphism study 
(Table 5). 
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Table 5   
Population subgroups within the Eskom study cohort according to HIV-1 status. 
 
Number (percent) of individuals 
Population group 
HIV-1 positive HIV-1 negative HIV-1 unknown 
Black (n=282) 
Ndebele (n=17) 
Pedi (n=23) 
South Sotho (n=20) 
Swazi (n=27) 
Tsonga (n=5) 
Tswana (n=25) 
Venda (n=22) 
Xhosa (n=46) 
Zulu (n=97) 
26 (9) 
2 (12) 
1 (4) 
3 (15) 
3 (11) 
0 (0) 
0 (0) 
0 (0) 
4 (9) 
13 (13) 
240 (85) 
15 (88) 
20 (87) 
17 (85) 
21 (78) 
5 (100) 
23 (92) 
22 (100) 
42 (91) 
75 (77) 
16 (6) 
0 (0) 
2 (9) 
0 (0) 
3 (11) 
0 (0) 
2 (8) 
0 (0) 
0 (0) 
9 (9) 
Caucasian  (n=102) 
English (n=52) 
Afrikaans (n=50) 
0 (0) 
0 (0) 
0 (0) 
102 (100) 
52 (100) 
50 (100) 
0 (0) 
0 (0) 
0 (0) 
 
 
 
2.2 Sample preparation 
 
2.2.1 Samples for enzyme-linked immunosorbent assays 
(ELISA) 
 
Plasma and PBMCs were previously isolated from whole blood samples 
collected by venipuncture into EDTA Vacutainers (Becton Dickinson).  Samples 
were processed immediately upon collection. 
 
Plasma was collected by centrifugation at 200 x g for 10 minutes at room 
temperature, and stored at -70°C. 
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Supernatants from PBMC cultures used in an earlier study (Meddows-Taylor et 
al., 1999a) were used for further testing of chemokines by ELISA.  Briefly, 
PBMCs were isolated from buffy coats by centrifuging phosphate-buffered 
saline (PBS) diluted whole blood (1:1) on a Ficoll-Paque (Amersham 
Biosciences, Uppsala, Sweden) gradient at 1000 x g for 30 minutes at room 
temperature.  Cells were counted by trypan blue exclusion, and diluted to 1.5 x 
106 cells/ml for plating in RPMI medium containing 1% L-glutamine (Invitrogen 
Corporation, Carlsbad, California, USA).  PBMCs were either unstimulated or 
stimulated with 12.5 µg/ml PHA (Sigma Chemical Co., St Louis, Missouri, USA), 
10% human serum (obtained from the South African Blood Transfusion Service, 
Johannesburg, South Africa) was added to each well, and cells were incubated 
for 24 hours at 37°C in a moist, 5% CO2 atmosphere.  Supernatants were then 
harvested and stored at -70°C. 
 
 
2.2.2 DNA extraction 
 
DNA was extracted from PBMCs that were previously isolated from blood 
samples and stored as cell pellets at -70°C, and from whole blood.  PBMC cell 
pellets (<5 x 106 cells) were thawed and 200 µl of PBS (at room temperature) 
added; alternatively, 200 µl of whole blood was equilibrated to room 
temperature.  Genomic DNA was extracted from PBMCs or whole blood using a 
QIAamp DNA Blood Minikit (QIAgen, Hilden, Germany) according to the 
manufacturer’s protocol.  Briefly, cells were lysed by incubation at 56°C for 10 
minutes with 20 µl of the kit protease and 200 µl of lysis buffer.  Two hundred µl 
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of 96% ethanol (EtOH) (Merck Chemicals (Pty) Ltd, Nottingham, UK) was 
added, and the entire sample applied to a spin column (containing a silica-gel 
membrane to which DNA binds specifically) and centrifuged.  Following washing 
steps to remove proteins and PCR inhibitors, the DNA was eluted from the 
column with 200 µl elution buffer by incubation at room temperature for 1 
minute, followed by centrifugation. 
 
 
2.2.3 DNA quantitation 
 
Extracted genomic DNA samples were tested using a NanoDrop (NanoDrop 
Technologies, Wilmington, Detroit, USA).  DNA samples with A260<0.1 were 
considered to be of low concentration, and with A260/230<0.5 of poor quality.  
These samples were excluded. 
 
 
2.3 ELISAs 
 
CCL3, CCL4 and CCL5 levels were determined using DuoSet ELISA 
Development Systems, while CXCL12 and CXCL8 levels were quantified using 
Quantikine ELISA kits (both from R&D Systems, Minneapolis, Minnesota, USA) 
according to the manufacturer’s directions.  Minimum detectable levels for these 
assays were <10 pg/ml for CCL3, 4 pg/ml for CCL4, 2 pg/ml for CCL5, 1.0 
pg/ml for CXCL12 and 1.5 pg/ml for CXCL8. 
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In these ELISAs, a capture antibody specific to each chemokine was 
immobilised on a plate, which was then washed of unbound antibody.  
Remaining binding sites on the plate were blocked with non-specific protein 
(bovine serum albumin, BSA).  The plasma or supernatant sample (diluted if 
necessary) was then added to each well, and the chemokine of interest bound 
to the capture antibody.  After washing to remove non-specific proteins, a 
detection antibody with the same specificity of the capture antibody was added, 
and any excess removed by a further wash step.  This detection antibody is 
conjugated to biotin, which was then bound by streptavidin conjugated to 
horseradish peroxidase (HRP).  The HRP enzyme catalyses a colour-change 
reaction (using a substrate oxidised by HRP using hydrogen peroxide as the 
oxidising agent), the absorbance of which was measured by spectrophotometer 
(measurement A450 – reference A540) and used to calculate the amount of target 
by reference to a standard curve generated for each plate (using a serial 
dilution of a control of known concentration).   
 
 
2.4 CCL3L1 gene copy number determination 
 
2.4.1 Real-time PCR analysis 
 
Real-time PCR was performed using an ABI PRISM 7500 (Applied Biosystems, 
Foster City, California, USA) according to the protocol supplied, using primers 
and probes as detailed in Table 6.  Briefly, each PCR reaction contained 
forward and reverse primers at 0.9 µM each, probe at 0.25 µM, 1x TaqMan 
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Universal PCR Master Mix (Applied Biosystems) and approximately 20 ng of 
genomic DNA.  PCR reactions were carried out using the manufacturer’s 
suggested profile of 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 
seconds and 60°C for 1 minute. 
 
 
Table 6   
Primers and probes synthesised (University of Cape Town, South Africa) for 
determination of CCL3 and CCL3L1 gene copy number.     
 
Primer / probe Sequence (5’->3’) Reference 
β-globin gene (forward) ggcaaccctaaggtgaaggc (Townson et al., 2002) 
β-globin gene (reverse) ggtgagccaggccatcacta (Townson et al., 2002) 
β-globin gene (probe)* catggcaagaaagtgctcggtgcct (Townson et al., 2002) 
CCL3L1 gene (forward) tctccacagcttcctaaccaaga (Townson et al., 2002) 
CCL3 gene (forward) tctccacagcttcctaaccaagc  
CCL3 / CCL3L1 genes (reverse) ctggacccactcctcactgg (Townson et al., 2002) 
CCL3 gene (probe)* aagccggcaggtctgtgctga  
CCL3L1 gene (probe)* aggccggcaggtctgtgctga (Townson et al., 2002) 
CCL3 / CCL3L1 genes (primer A) ccgagtcacagctcagaaga Dr M Paximadis, 
unpublished data 
CCL3 / CCL3L1 genes (primer B) ccacagcatcagcccat Dr M Paximadis, 
unpublished data 
 
* All probes were labelled with a 5’ FAM (6-carboxyfluorescein) reporter dye and a 3’ TAMRA 
(carboxytetramethyl- rhodamine) quencher. 
 
 
 
For each sample, the β-globin, CCL3 and CCL3L1 genes were amplified in 
duplicate.  The CCL3 and CCL3L1 genes were distinguished on the basis of a 
SNP at the 3’ terminal position of the forward primer site (Figure 12).  CCL3 
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gene copy number was confirmed at 2 copies per diploid genome (pdg) for each 
sample, calculated using the Relative Quantification method (as per the protocol 
supplied) and using β-globin (present at 2 copies pdg) as the endogenous 
control.  Due to the similarity of the primers for CCL3 and CCL3L1, CCL3 was 
preferentially used as the endogenous control to calculate CCL3L1 gene copy 
number, again using the Relative Quantification method.   
 
 
 
CCL3   tctccacagcTTCCTAACCAAGCGAAGCCGGCAGGTCTGTGCTGACCCCAGTGAGGAGTGGGTCCAG 
       |||||||||||||||||||||| || ||||||||||||||||||||||||||||||||||||||||| 
CCL3L1 tctccacagcTTCCTAACCAAGAGAGGCCGGCAGGTCTGTGCTGACCCCAGTGAGGAGTGGGTCCAG 
 
 
 Intron 2  Exon 3 
 
 
Figure 12   
CCL3 and CCL3L1 real-time PCR primer and probe sites.   
Nucleotide site allowing PCR discrimination between CCL3 and CCL3L1 is in 
bold. 
 
 
 
DNA samples giving a result of CCL3 gene copy ≠ 2 were found to be of low 
concentration (A260<0.1) and/or poor quality (A260/230<0.5), and were excluded 
from analyses.  
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2.4.2 PCR method for CCL3 and CCL3L1 gene detection  
 
PCR primers A and B (Table 6) were synthesised to amplify the promoter and 
exon 1 of the CCL3 and CCL3L1 genes.  Due to a 312 bp Alu element insertion 
within the 5’ region of CCL3L1 compared to CCL3 (Figure 13), CCL3 and 
CCL3L1 were able to be distinguished on the basis of PCR product size by 
agarose gel electrophoresis.   
 
 
Core promoter
Alu element Exon 1 Exon 2
Core promoter
Exon 1 Exon 2CCL3
CCL3L1
Primer B
Primer B
Primer A
Primer A
PCR product
1240 bp
PCR product
1550 bp
 
 
Figure 13   
CCL3 and CCL3L1 promoter and partial gene structure, showing Alu element 
insertion in CCL3L1 and primer positions. 
 
 
 
Briefly, each PCR reaction contained forward and reverse primers at 300 nM 
each, 200 µM of each dNTP (Promega Corporation, Madison, Wisconsin, USA), 
200 ng of template DNA, 1x Expand High Fidelity Buffer and 2.6 U of Expand 
High Fidelity enzyme mix (Roche Diagnostics GmbH, Mannheim, Germany), 
made up to 50 µl with sterile dH2O.  PCR reactions were carried out using the 
Expand High Fidelity protocol of 94°C for 2 minutes, 10 cycles of 94°C for 15 
seconds, 60°C for 30 seconds and 68°C for 1.5 minutes, 20 cycles of 94°C for 
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15 seconds, 60°C for 30 seconds and 72°C for 45 seconds to 8 minutes 
(increasing by 5 seconds each cycle), followed by a final elongation of 72°C for 
7 minutes.  PCR products were run on 1% agarose (Bioline, London, UK) 
containing 0.5 µg/ml ethidium bromide (CLP, San Diego, California, USA), at 
100V for 1 hour, in 0.5x TBE buffer (Invitrogen Corporation).   
 
 
2.4.3 DNA sequencing 
 
PCR products were extracted using the QIAquick PCR Purification Kit (QIAgen), 
according to the manufacturer’s instructions.  Briefly, PCR products were bound 
specifically to the silica-gel membrane of a spin column.  Following washing 
steps to remove unincorporated PCR components and primers, PCR products 
were eluted with 30 µl buffer (10 mM Tris-Cl, pH 8.5). 
 
Sequencing was performed using the BigDye® Terminator v3.1 Cycle 
Sequencing Kit (Applied Biosystems) according to the manufacturer’s protocol.  
Sequencing reactions consisted of approximately 20 ng purified PCR product 
(estimated from the intensity of the PCR band seen on ethidium bromide-
stained agarose gel, in comparison to size standards of known concentration – 
for a bright band, 1 µl of PCR product was used, for a fainter band, 2 µl), 3.2 
pmol primer and 4 µl BigDye® reaction mix, made up to 10 µl with dH2O.  
Reactions were carried out in a 96-well plate on a GeneAmp PCR System 9700 
(Applied Biosystems) by denaturing at 96°C for 1 minute, followed by 25 cycles 
of 96°C for 10 seconds, 50°C for 5 seconds and 60°C for 4 minutes.   
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Sequencing products were purified, according to the manufacturer’s protocol, by 
precipitation with 25 µl of freshly mixed 3M sodium acetate (NaOAc) pH 4.6 
(Merck) and absolute EtOH (Merck) (1:25), and centrifuged at room 
temperature for 30 minutes at 2000 x g.  Supernatant was removed by inverting 
the plates onto paper towels and centrifuging for 1 minute at 150 x g.  
Sequenced products were washed with 50 µl of 70% EtOH, centrifuged for 5 
minutes at 2000 x g, and supernatant removed as before.  Plates were placed 
open at 63°C for 3 minutes to dry completely before the addition of deionised 
formamide for running on an ABI Prism 3100 Genetic Analyser (Applied 
Biosystems).  Sequences were analysed using the proprietary software 
installed. 
 
 
2.5 IL8-251T→A SNP determination 
 
2.5.1 IL8-251T→A SNP PCR and agarose gel electrophoresis 
 
The following primers were synthesised (University of Cape Town) (Figure 14):  
 
(1) IL8-251 consensus 1 5’-tgccccttcactctgttaac-3’ (Hull et al., 2001) 
(2) IL8-251A 5’-ccacaatttggtgaattatcaat-3’ and 
IL8-251T 5’-ccacaatttggtgaattatcaaa-3’ (Hull et al., 2001) 
(3) IL8-251 consensus 2 5’-gctggcttatcttcaccatc-3’ 
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Untranslated regions
Translated protein sequences
Exon 1 Exon 2 Exon 3
CXCL8
Introns
Exon 41
3
2
PCR primers:
1 = IL8-251 consensus 1
2 = IL8-
251 consensus 23 = IL8-
251 A/T
IL8-251A/T SNPIL8-251T→ A SNP
 
 
 
Figure 14   
CXCL8 gene structure showing position of PCR primers and -251 SNP. 
 
 
 
PCR was initially performed as described (Hull et al., 2001), with the annealing 
temperature modified as described below.  The PCR mix consisted of 1x PCR 
buffer and 5 U Taq DNA polymerase (Promega Corporation), with 1.5 mM 
MgCl2 (Promega Corporation), 200 µM of each dNTP (Promega Corporation), 1 
µM of each primer, and approximately 50 ng of genomic DNA in a final volume 
of 50 µl.  Thermal cycling conditions were 94°C for 2 minutes, followed by 10 
cycles of 94°C for 15 seconds, 68°C (decreasing by 1°C each cycle) for 30 
seconds, 72°C for 30 seconds, followed by 20 cycles of 94°C for 15 seconds, 
58°C for 30 seconds, 72°C for 30 seconds, followed by 72°C for 3 minutes and 
a 4°C hold.  PCR products were run on 2% agarose (Bioline) containing 0.5 
µg/ml ethidium bromide (CLP), at 70V for 1 hour, using the Electro-Fast Stretch 
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108 Gel Tank System (ABgene Ltd., Epsom, UK), in 1x TBE buffer (Invitrogen 
Corporation).  This system allows high-throughput agarose-based detection of 
PCR products – 96 PCR amplification reactions were carried out in a 96-well 
plate format, in parallel, with primers specific for the T- and A-alleles 
(combinations of primer 1 and each primer 2, separately.  Primer 3 was used for 
confirmation purposes). 
 
 
2.5.2 IL8-251T→A SNP real-time PCR 
 
Although the system described above allows high-throughput agarose gel-
based detection of PCR products, real-time PCR systems provide faster 
throughput as PCR products are detected during amplification as opposed to 
subsequently, by electrophoresis.  Real-time PCR was therefore developed for 
the detection of the IL8-251T→A polymorphism, using the ABI PRISM 7500 
(Applied Biosystems).  The same primers as described before were used, with 
incorporation of SYBR Green as a reporter dye (Applied Biosystems).  Thermal 
cycling conditions were 95°C for 10 minutes, followed by 40 cycles of 95°C for 
15 seconds, 55°C for 15 seconds, 60°C for 1 minute.  Thermal cycling was 
followed by a dissociation stage of 95°C for 15 seconds, 60°C for 1 minute, then 
95°C for 15 seconds (as recommended by the manufacturer) to ensure single 
PCR product. 
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2.6 Statistical methods 
 
All statistical analyses were performed using SPSS version 15.0 software 
(SPSS Inc., Chicago, Illinois, USA).  Differences in levels of chemokines and in 
CCL3L1 gene copy numbers between groups were compared using the 
nonparametric Mann Whitney U test.  Correlations between chemokine levels 
were calculated by bivariate Spearman’s rank coefficients, while Fisher’s Exact 
test was used to compare proportions of individuals with detectable chemokine 
levels, and with the IL8-251T→A SNP.  For all statistical tests, significance was 
considered to be P<0.05. 
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CHAPTER 3 
 
INFLUENCE OF HIV-1 AND TB ON CHEMOKINE PRODUCTION 
 
 
3.1 Introduction 
 
The chemokines CCL3, CCL4, CCL5 and CXCL12 (previously known as MIP-
1α, MIP-1β, RANTES and SDF-1α, respectively) are of particular interest in 
HIV-1 research, since they are the natural ligands of the HIV-1 coreceptors 
CCR5 (CCL3, CCL4 and CCL5) and CXCR4 (CXCL12).  CCL3, CCL4 and 
CCL5 are all inhibitors of HIV-1 binding, partly due to steric hindrance through 
the blocking of their receptor CCR5 (Cocchi et al., 1995).  In addition, 
desensitisation and internalisation of CCR5 through ligand binding also plays a 
role in reducing the targets for HIV-1 binding (Amara et al., 1997).  Most 
important, although less well understood, is the complex interaction of immune 
system components in chemokine-induced immune cell recruitment and 
regulation, including (but not limited to) the development of Th1 and Th2 
responses. 
 
According to one report (Jennes et al., 2004), intracellular levels of the 
chemokines CCL3 and CCL4 tend to be increased in lymphocytes during HIV-1 
infection, with a corresponding decrease in their PHA-stimulated secretion into 
lymphocyte culture supernatants; CCL5 tends to be increased both 
intracellularly and in culture supernatant.  In the same patients, after more than 
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3 years of HAART, intracellular levels of CCL4 and CCL5, and CCL3 and CCL4 
in supernatant, reached normal levels, coincident with higher CD4+ T cell counts 
(Jennes et al., 2004).  In contrast, data from our laboratory has shown that 
amongst a cohort of antenatal ART-naïve HIV-1 infected women, PHA-
stimulated production of CCL3, CCL4 and CCL5 by PBMCs was increased by 
HIV-1 infection (Meddows-Taylor et al., 2006). 
 
CXCL8 (previously known as IL-8) is a CXC chemokine important in the 
inflammatory process, and is produced predominantly by monocytes/ 
macrophages (Yoshimura et al., 1987) in response to a wide variety of 
microorganisms (Chensue, 2001).  CXCL8 is involved in recruiting leukocytes to 
inflammatory sites (Pace et al., 1999), but if overproduced can cause bystander 
damage (Chensue, 2001).   
 
The role of CXCL8 in TB is of interest, as elevated levels of CXCL8 are 
associated with more severe disease (Friedland et al., 1995, Mastroianni et al., 
1994).  However, CXCL8 is up-regulated in macrophages as part of the 
macrophage activation program in response to Mtb infection (Ribeiro-Rodrigues 
et al., 2002), and seems to be essential for host defence to Mtb (Larsen et al., 
1995).  It is therefore essential for efficient control of infection by the immune 
system that CXCL8 expression is tightly regulated. 
 
CXCL8 levels are upregulated in both serum (Matsumoto et al., 1993) and 
plasma (Meddows-Taylor et al., 1999a, Thea et al., 1996) of HIV-1 infected 
adults, although not in HIV-1 infected children (Meddows-Taylor et al., 2001b).  
 60 
CXCL8 can either decrease or increase HIV-1 replication in promonocytic U1 
cells on induction by proinflammatory cytokines, depending on the nature of the 
cytokine and CXCL8 concentration (Tiemessen et al., 2000a).  The down-
regulation of CXCL8 receptors seen in HIV-1, and in coinfection with HIV-1 and 
Mtb, may be modulated by the up-regulation of CXCL8 itself, or alternatively by 
altered recycling of the receptors (Meddows-Taylor et al., 1998). 
 
In this section of the study, we aimed to examine the relationships between 
levels of the chemokines CCL3, CCL4, CCL5, CXCL12 and CXCL8, with 
particular relevance to infection by HIV-1 and Mtb.  The study comprised two 
components, namely examination of plasma chemokine levels using samples 
from HIV-TB coh1, and the study of previously stored PBMC supernatants from 
HIV-TB coh2 (Chapter 2.1.1).   
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3.2 Results 
 
3.2.1 Chemokine levels in plasma samples 
 
3.2.1.1 Influence of age, gender and race 
 
As the groups within the HIV-TB coh1 study cohort (Chapter 2.1.1, Table 2) 
were not matched for age, gender or race, the influence of these variables on 
plasma levels of CCL3, CCL4, CCL5, CXCL12 and CXCL8 was first examined 
in the control group (n=82) of this cohort.  The aim of these comparisons was to 
ensure that groups used for further analyses could be meaningfully compared.   
 
Age and gender had no effect on any of the studied chemokines (data not 
shown).  However, in comparisons of Black and Caucasian individuals, race 
group was seen to influence plasma CCL3 levels (Figure 15), although levels of 
the other chemokines were unaffected (data not shown).  Circulating levels of 
CCL3 were significantly elevated in Caucasians, with the majority of Black 
individuals having undetectable levels of this chemokine.  For this reason, 
Caucasians were omitted from further analyses in this Chapter, due to their 
smaller numbers in the control and HIV-1 groups within HIV-TB coh1.   
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Figure 15   
CCL3 plasma levels in Black and Caucasian individuals from the control group. 
Data are presented as medians (horizontal bar), 25th and 75th percentiles 
(boxes), 10th and 90th percentiles (bars) and extremes (*). 
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3.2.1.2 Influence of clinical status and treatment on 
plasma chemokine levels 
 
In Black individuals from the HIV-1 group of HIV-TB coh1 (Table 2), no 
significant differences in plasma chemokine levels were seen when comparing 
those patients who remained asymptomatic (n=26) with those with AIDS-
defining illnesses (n=13) (data not shown; P>0.05). 
 
Within the TB groups (TB and HIV-1/TB), the influence of antituberculosis 
therapy on plasma chemokine levels could not be tested, since only 2 
individuals were not treated, and 5 were of unknown treatment status.   
 
The effect of ART on plasma chemokine levels in Black individuals from the 
HIV-1 group (n=26) of HIV-TB coh1 was compared.  ART-positive individuals 
had a trend towards dimished levels of CCL3 (P=0.095), and had significantly 
decreased levels of CXCL12 relative to untreated HIV-1 infected individuals 
(P=0.034) (Figure 16).  For this reason, further analyses were restricted to ART-
naïve HIV-1 positive patients (Table 3).   
 64 
Antiretroviral treatment
negativepositive
CC
L3
 
(p
g/
m
l)
400
300
200
100
0
N= 179
CC
L4
 
(p
g/
m
l)
60
40
20
0
Antiretroviral treatment
negativepositive
N= 179
Antiretroviral treatment
negativepositive
N= 179
CC
L5
 
(p
g/
m
l)
1200
1000
800
600
400
Antiretroviral treatment
negativepositive
N= 179
CX
CL
12
 
(p
g/
m
l)
4000
3500
3000
2500
2000
1500
P=0.034
Antiretroviral treatment
negativepositive
N= 179
CX
CL
8 
(p
g/
m
l)
50
40
30
20
10
0
b
c d
e
a
CC
L3
 
(p
g/
m
l)
CC
L4
 
(p
g/
m
l)
CC
L5
 
(p
g/
m
l)
CX
CL
12
 
(p
g/
m
l)
CX
CL
8 
(p
g/
m
l)
 
 
Figure 16   
CCL3 (a), CCL4 (b), CCL5 (c), CXCL12 (d) and CXCL8 (e) levels in plasma 
samples from Black HIV-1 positive patients stratified according to ART status. 
Data are presented as medians (horizontal bar), 25th and 75th percentiles 
(boxes), 10th and 90th percentiles (bars), outliers (o) and extremes (*). 
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3.2.1.3 Plasma chemokine levels in HIV-1 and TB 
 
Chemokine levels in plasma samples from Black ART-negative patients with 
HIV-1, TB, or HIV-1/TB coinfection were compared with uninfected controls 
(Chapter 2.1.1, Table 3) (Figure 17).  The following results were noted: 
 
• CCL3 levels (Figure 17a) were significantly raised by infection with HIV-1, 
Mtb, or both (P=0.002, P=0.001, P<0.001 respectively).   
• CCL4 levels (Figure 17b) in the HIV-1, TB and HIV-1/TB groups were 
significantly different from controls, in that infection (by HIV-1 or Mtb, or both) 
significantly increased levels (P=0.004, P=0.003, P=0.007 respectively), the 
statistical finding clearly driven by the small proportions of individuals with 
detectable levels.  CCL4 was detectable in 1/49 (2%) controls, 4/17 (24%) 
HIV-1, 6/27 (22%) TB and 11/61 (18%) HIV-1/TB individuals. 
• CCL5 levels (Figure 17c) were significantly raised by HIV-1 and Mtb infections 
alone or together (P<0.001 in each case). 
• CXCL12 levels (Figure 17d) were significantly increased in all infection 
groups, with HIV-1 (in both HIV-1 and HIV-1/TB groups) driving higher levels 
than Mtb infection alone (P<0.001 in each case). 
• CXCL8 (Figure 17e) was detectable in more HIV-1 infected individuals (HIV-1 
and HIV-1/TB groups 13/78; 17%) than HIV-1 uninfected (control and TB 1/76; 
1.3%) (P=0.001; Fisher’s Exact test), while more individuals in the HIV-1/TB 
group had detectable levels of CXCL8 (12/61, 20%) than in the control group 
(0/49) (P=0.001; Fisher’s Exact test).  In the HIV-1/TB group, CXCL8 levels 
were significantly raised relative to controls (P=0.001; Mann Whitney U test).   
 66 
TB HIV-1/TBHIV-1control
N= 61271749
CC
L3
 
(p
g/
m
l)
300
200
100
0
P=0.002
P=0.001
P<0.001
CC
L5
 
(p
g/
m
l)
1200
1000
800
600
400
200
P<0.001
P<0.001
P<0.001
CX
CL
12
 
(p
g/
m
l)
4000
3500
3000
2500
2000
1500
1000
P<0.001
P<0.001
P<0.001
P<0.001P<0.001
CX
CL
8 
(p
g/
m
l)
80
60
40
20
0
P=0.001
CC
L4
 
(p
g/
m
l)
125
100
75
50
25
0
TB HIV-1/TBHIV-1control
N= 61271749
TB HIV-1/TBHIV-1control
N= 61271749
TB HIV-1/TBHIV-1control
N= 61271749
TB HIV-1/TBHIV-1control
N= 61271749
P=0.004
P=0.003
P=0.007
c
e
d
ba
CC
L3
 
(p
g/
m
l)
CC
L5
 
(p
g/
m
l)
CX
CL
12
 
(p
g/
m
l)
CX
CL
8 
(p
g/
m
l)
CC
L4
 
(p
g/
m
l)
 
 
Figure 17   
CCL3 (a), CCL4 (b), CCL5 (c), CXCL12 (d) and CXCL8 (e) levels in plasma 
samples from Black uninfected control, HIV-1, TB and HIV-1/TB groups. 
Data are presented as medians (horizontal bar), 25th and 75th percentiles 
(boxes), 10th and 90th percentiles (bars), outliers (o) and extremes (*). 
 
 67 
3.2.2 Chemokine levels in PBMC culture supernatants 
 
Chemokine levels in PBMC culture supernatants from patients in HIV-TB coh2 
(Chapter 2.1.1) infected with HIV-1, TB, or HIV-1 and TB (HIV-1/TB) were 
compared with uninfected controls.  Unstimulated cell culture supernatants were 
tested, together with PHA-stimulated cells to determine chemokine production 
capacity.  Note that 16 individuals from each group were tested; where the 
numbers within each group drop below 16 (sample numbers as shown in the 
Figures), this indicates that there was insufficient sample for testing. 
 
In unstimulated PBMCs, levels of CCL3 were marginally but significantly 
increased by HIV-1 infection only (P=0.021).  In PHA-stimulated PBMCs, Mtb 
infection significantly reduced the capacity of cells to produce CCL3, with 
(P=0.002) or without (P=0.035) coinfection with HIV-1.  HIV-1 infection alone 
reduced PHA-induced production of CCL3, although statistical significance was 
not reached (P=0.086) (Figure 18). 
 
CCL4 levels in unstimulated PBMC cultures were unchanged by infection in any 
of the groups.  PHA-induced CCL4 production was unaffected by HIV-1 
infection, but was significantly reduced from controls in HIV-1/TB coinfected 
individuals (P=0.007).  There was a trend to reduced CCL4 production in the 
presence of TB alone (P=0.067) (Figure 19). 
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Figure 18   
CCL3 levels in PBMC culture supernatants (unstimulated and PHA-stimulated) 
from uninfected control, HIV-1, TB and HIV-1/TB groups. 
Data are presented as medians (horizontal bar), 25th and 75th percentiles 
(boxes), 10th and 90th percentiles (bars), outliers (o) and extremes (*). 
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Figure 19   
CCL4 levels in PBMC culture supernatants (unstimulated and PHA-stimulated) 
from uninfected control, HIV-1, TB and HIV-1/TB groups. 
Data are presented as medians (horizontal bar), 25th and 75th percentiles 
(boxes), 10th and 90th percentiles (bars), outliers (o) and extremes (*). 
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In unstimulated PBMC culture, levels of CCL5 were reduced in response to TB 
infection regardless of HIV-1 status; significant differences were only seen when 
comparing the HIV-1 group with the HIV-1/TB coinfected group (P=0.031).  
PHA-induced production of CCL5 was significantly increased by HIV-1 infection 
(P=0.026), but significantly reduced in HIV-1/TB coinfection (P=0.014), while 
showing a trend towards reduction in TB alone (P=0.733) (Figure 20). 
 
Unstimulated CXCL8 production was not significantly affected by infection in 
any of the groups.  There was a trend towards reduced PHA-stimulated CXCL8 
production in the TB group (P=0.086), with significant reductions in HIV-1 
infection (P=0.012).  The most significant reduction in CXCL8 production was 
seen in dual HIV-1/TB infection (P=0.001) (Figure 21). 
 
There were no detectable levels of CXCL12 in any of the PBMC culture 
supernatant samples, whether unstimulated or PHA-stimulated (data not 
shown). 
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Figure 20   
CCL5 levels in PBMC culture supernatants (unstimulated and PHA-stimulated) 
from uninfected control, HIV-1, TB and HIV-1/TB groups. 
Data are presented as medians (horizontal bar), 25th and 75th percentiles 
(boxes), 10th and 90th percentiles (bars), outliers (o) and extremes (*). 
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Figure 21   
CXCL8 levels in PBMC culture supernatants (unstimulated and PHA-stimulated) 
from uninfected control, HIV-1, TB and HIV-1/TB groups. 
Data are presented as medians (horizontal bar), 25th and 75th percentiles 
(boxes), 10th and 90th percentiles (bars), outliers (o) and extremes (*). 
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3.2.3 Relationships between chemokines 
 
3.2.3.1 Chemokine levels in the periphery 
 
Plasma samples tested included all Black, ART-naïve individuals from HIV-TB 
coh1 (Chapter 2.1.1, Table 3).  Relationships between each of the chemokines 
tested were examined (Table 7); CCL4 was excluded from comparisons as only 
a small proportion of the total number of samples (n=22/154; 14%) had 
detectable plasma levels of CCL4.  CXCL8 was similarly excluded, as even 
fewer samples (n=15/154; 10%) had detectable plasma levels of CXCL8. 
 
The strongest correlation noted was a positive correlation between the levels of 
CCL5 and CXCL12 (P<0.001).  There were weaker correlations between CCL3 
and CCL5 (P=0.004), and CCL3 and CXCL12 (P<0.001), only when all samples 
were included.  No correlations were observed when any of the groups were 
analysed separately, indicating that no group in particular was responsible for 
the relationships detected, but that increased sample number gave rise to the 
relationships noted when the groups were combined. 
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Table 7   
Correlations between levels of plasma chemokines in Black, ART-negative 
individuals from HIV-TB coh1.   
 
Comparison All samples Controls HIV-1 TB HIV-1/TB 
CCL3 vs. CCL5 
n=153 
R=0.233** 
P=0.004 
n=49 
R=-0.036 
P>0.05 
n=17 
R=0.085 
P>0.05 
n=27 
R=-0.081 
P>0.05 
n=60 
R=-0.019 
P>0.05 
CCL3 vs. CXCL12 
n=154 
R=0.399** 
P<0.001 
n=49 
R=-0.207 
P>0.05 
n=17 
R=0.253 
P>0.05 
n=27 
R=0.173 
P>0.05 
n=61 
R=0.227 
P>0.05 
CCL5 vs. CXCL12 
n=153 
R=0.497** 
P<0.001 
n=49 
R=0.012 
P>0.05 
n=17 
R=0.176 
P>0.05 
n=27 
R=0.117 
P>0.05 
n=60 
R=-0.089 
P>0.05 
 
** Correlation is significant at the 0.01 level (2-tailed). 
 
 
3.2.3.2 Ex vivo cellular chemokine production 
 
PBMC culture supernatants (unstimulated and PHA-stimulated) from all groups 
within HIV-TB coh2 (Chapter 2.1.1) were tested for relationships between the 
levels of each of the chemokines.  CXCL12 was excluded from these 
comparisons, as no detectable levels of CXCL12 were produced by 
unstimulated or PHA-stimulated PBMCs. 
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In unstimulated PBMCs (Figure 22), there was a significant positive correlation 
between the levels of CCL3 and CCL4 in all groups combined (P<0.001).  The 
cohort was not sub-divided into the separate groups (control, HIV-1, TB and 
HIV-1/TB) for all correlations due to the small sample numbers in each 
individual group.  However, despite the smaller numbers in each group, the 
positive relationships noted between these chemokines remained, although 
statistical significance was lost (data not shown).  No relationship between 
CCL3 and CCL5 was seen, contrasting with the weak correlation seen for these 
chemokines in plasma samples, while CCL5 and CXCL8 showed an inverse 
relationship (P=0.018).  There were weak but significant correlations between 
CCL4 and CCL5 (P=0.010), and CCL3 and CXCL8 (P=0.020). 
 
In PHA-stimulated PBMCs from all groups, strong positive correlations between 
production capacities of CCL3, CCL4 and CCL5 were observed (P<0.001 in 
each case) (Figure 23a-c).  In addition, positive, but weaker, correlations were 
noted for CCL3-CXCL8 (P<0.001) and CCL4-CXCL8 (P=0.001) (Figure 23d,e). 
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Figure 22   
Correlations between levels of chemokines in unstimulated PBMC supernatant 
samples from all groups. 
CCL3 vs. CCL4 (a), CCL3 vs. CCL5 (b), CCL4 vs. CCL5 (c), CCL3 vs. CXCL8 
(d), CCL4 vs. CXCL8 (e) and CCL5 vs. CXCL8 (f). 
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Figure 23   
Correlations between chemokine production in PHA-stimulated PBMC 
supernatant samples from all groups. 
CCL3 vs. CCL4 (a), CCL3 vs. CCL5 (b), CCL4 vs. CCL5 (c), CCL3 vs. CXCL8 
(d), CCL4 vs. CXCL8 (e) and CCL5 vs. CXCL8 (f). 
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When PHA-stimulated production of chemokines was examined in each of the 
groups within HIV-TB coh2, it became clear which in vivo stimuli (infecting 
organism/s) were predominantly contributing to the relationships noted (Table 
8).  Comparisons between CCL3-CCL4, CCL4-CCL5 and CCL3-CCL5 showed 
contributions by all groups, although the presence of TB influenced CCL4 
comparisons to the greatest extent.  CCL3-CXCL8 comparisons showed 
greatest contributions from HIV-1 and TB groups, while CCL4-CXCL8 and 
CCL5-CXCL8 relationships were driven primarily by TB. 
 
 
Table 8   
Correlations between levels of PHA-stimulated chemokines in HIV-TB coh2.   
 
Comparison All samples Controls HIV-1 TB HIV-1/TB 
CCL3 vs. CCL4 
n=64 
R=0.879** 
P<0.001 
n=16 
R=0.682** 
P=0.004 
n=16 
R=0.636** 
P=0.008 
n=16 
R=0.929** 
P<0.001 
n=16 
R=0.964** 
P<0.001 
CCL3 vs. CCL5 
n=64 
R=0.735** 
P<0.001 
n=16 
R=0.688** 
P=0.003 
n=16 
R=0.556* 
P=0.025 
n=16 
R=0.650** 
P=0.006 
n=16 
R=0.658** 
P=0.006 
CCL4 vs. CCL5 
n=64 
R=0.806** 
P<0.001 
n=16 
R=0.668** 
P=0.005 
n=16 
R=0.693** 
P=0.003 
n=16 
R=0.739** 
P=0.001 
n=16 
R=0.744** 
P=0.001 
CCL3 vs. CXCL8 
n=64 
R=0.519** 
P<0.001 
n=16 
R=-0.468 
P>0.05 
n=16 
R=0.671** 
P=0.004 
n=16 
R=0.776** 
P<0.001 
n=16 
R=0.497 
P>0.05 
CCL4 vs. CXCL8 
n=64 
R=0.390** 
P=0.001 
n=16 
R=-0.402 
P>0.05 
n=16 
R=0.194 
P>0.05 
n=16 
R=0.834** 
P<0.001 
n=16 
R=0.419 
P>0.05 
CCL5 vs. CXCL8 
n=64 
R=0.219 
P>0.05 
n=16 
R=-0.446 
P>0.05 
n=16 
R=0.018 
P>0.05 
n=16 
R=0.547* 
P=0.028 
n=16 
R=0.018 
P>0.05 
 
* Correlation is significant at the 0.05 level (2-tailed). 
** Correlation is significant at the 0.01 level (2-tailed). 
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3.3 Discussion 
 
Establishing the levels of chemokines is of great importance in the study of HIV-
1 and TB, due to their effect on immunity (both innate and acquired) and hence 
on susceptibility to and progression of disease.  Our study focussed on the 
relationships between 5 chemokines which are of particular relevance to HIV-1 
and TB, namely the CCR5 ligands CCL3, CCL4 and CCL5, CXCR4 ligand 
CXCL12, and CXCL8.  We examined these chemokines in plasma in order to 
establish their in vivo levels (which reflect immune events that have already 
occurred), in unstimulated PBMCs (a measure of spontaneous ex vivo 
production, which is likely to be influenced by prior in vivo immune events), and 
in PHA-stimulated PBMCs (a measure of ex vivo induced cellular production). 
 
The determination of chemokine levels in plasma samples showed firstly that 
both race group and ART had an influence (on CCL3 and CXCL12 levels, 
respectively), which led us to restrict the cohort used to Black ART-naïve 
individuals.  The influence of antimycobacterial drugs could not be determined 
in TB and HIV-1/TB patients due to the fact that most of the individuals with TB 
were on antimycobacterial therapy.   
 
In general, plasma levels of all the chemokines tested were raised in response 
to infection with HIV-1, Mtb and both organisms, suggesting that increased 
immune activation that accompanies these infections results in higher 
peripheral circulating chemokine levels.  CXCL8 has been shown to be 
increased in active TB infection (Friedland et al., 1995, Sahiratmadja et al., 
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2007), but here was only significantly increased in HIV-1/TB patients, with very 
few TB-positive individuals having detectable levels (possibly due to the fact 
that all were on anti-TB therapy - proinflammatory cytokines are known to be 
increased in active TB, while anti-inflammatory cytokines increase during 
therapy (Sahiratmadja et al., 2007)).  
 
In general, chemokine production by unstimulated PBMCs was not strongly 
influenced by infection; however, large changes were seen in the ex vivo 
induced cellular production of chemokines when PHA was used as a mitogen.  
The presence of HIV-1 infection was accompanied by decreased CCL3 and 
CXCL8 production, did not affect CCL4 but increased CCL5 production.  On the 
other hand, the presence of pulmonary TB decreased PHA-induced production 
of all the CC chemokines and CXCL8; this was further exacerbated (for most 
chemokines) by coinfection with HIV-1.  PBMC cultures, both unstimulated and 
PHA-stimulated, did not produce detectable levels of CXCL12.  This can be 
explained by the fact that CXCL12 is produced primarily by endothelial cells and 
is not expressed constitutively by PBMCs (Pablos et al., 2003).  The elevated 
levels found in plasma were therefore most likely produced by activated 
endothelial cells. 
 
There were strong positive correlations noted between levels produced of each 
of the CC chemokines in PHA-stimulated PBMC culture supernatants 
(independent of infection status), possibly because they are all are produced by 
similar cell types, for example CD8+ T cells, and are likely to be regulated in a 
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coordinated fashion.  It was interesting that TB influenced the CCL4 and CXCL8 
comparisons to the greatest extent. 
 
It should be noted that although the same numbers of cells were used in each 
culture, composition of the different cell types can be altered by infection – for 
example, HIV-1 infection tends to increase the numbers of CD8+ T cells, and 
decreases numbers of CD4+ T cells with disease progression.  This could have 
an influence on the results obtained.  Aside from possible alterations in cell 
numbers, an explanation for the reduced ex vivo cellular responsiveness to 
PHA can be provided by chronic immune activation (Hazenberg et al., 2003) (as 
reflected by increased plasma levels of chemokines in HIV-1 and TB), which 
causes persistent immune stimulation in vivo with resulting T cell anergy (Bangs 
et al., 2006, Empson et al., 1999). 
 
It would be interesting in the future to identify the specific populations of cell 
types that are producing these particular chemokines and relating these to 
markers of disease progression, such as viral load and CD4+ T cell count in 
HIV-1 infected patients. 
 
Future work should involve larger groups of individuals, particularly in studies of 
plasma chemokine levels between HIV-1, TB and HIV-1/TB groups for which 
our numbers were low; it is becoming difficult to obtain prospective samples 
from TB patients who are not HIV-1 infected.  In addition, chemokine levels in 
individuals during the acute phase of HIV-1 infection, and during reactivation of 
latent TB, would be of great interest.  The numbers of supernatant samples 
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from HIV-TB coh2 were too low for many comparisons, and insufficient sample 
volume for some reduced numbers even further.  Further studies using larger 
cohorts would strengthen the statistical power to draw conclusions from 
chemokine measurements and correlations. 
 
The chemokines we have studied might be expected to be linked in their 
regulation since they form integral parts of similar immune pathways.  These 
results have demonstrated the influence of infection, both retroviral and 
mycobacterial, on the regulation of chemokine production, which in turn may 
influence disease progression and the immune response to further opportunistic 
infections.  What is clear from this study is that HIV-1 and TB result in 
dysregulated chemokine production, the consequences of which would be 
altered chemokine-induced functions such as chemotaxis (Matsukawa et al., 
2000).  Altered chemokine production would be expected to result in changes in 
chemokine gradients that could affect both cell numbers and composition of cell 
types entering into an immune response to further challenge.  
 
Studies of the regulation of chemokines in infection are of great importance to 
the development of effective therapies, since the design of these depends on 
gaining an understanding of both the correlates of protective immunity, and the 
dysregulation of the immune system seen in chronic HIV-1 and Mtb infections.  
 
 83 
CHAPTER 4 
 
CCL3L1 GENE COPY NUMBER IN SOUTH AFRICAN 
POPULATION GROUPS, AND AS A FACTOR CONTRIBUTING 
TO SUSCEPTIBILITY TO HIV-1  
 
 
4.1 Introduction 
 
In humans, the chemokine CCL3 is encoded by two functional genes, CCL3 
(present at 2 copies pdg) and CCL3L1, present at variable copy number (Irving 
et al., 1990, Nakao et al., 1990).  In addition, there is a non-functional pseudo-
gene, LD78γ.  Despite 94% nucleotide homology between the two functional 
genes (Nakao et al., 1990), CCL3L1 is a biologically distinct protein in that, in 
addition to binding CCR1 and CCR5, it can bind to receptor CCR3.  CCL3L1 is 
also a more potent agonist of CCR5 than CCL3 in that, unlike CCL3, it can be 
cleaved by CD26 (a membrane-associated serine protease dipeptidyl 
peptidase) to generate a –2 variant that has 30-fold higher affinity for CCR1 and 
CCR5 (Proost et al., 2000).  This makes CCL3L1 the most potent known natural 
inhibitor of HIV-1 entry. 
 
It is likely that gene duplication (estimated to have occurred 10 million years ago 
(Nakao et al., 1990)) generated the ancestral forms of the CCL3, CCL3L1, 
CCL4 and CCL4L1 genes, which were then preserved due to the evolution of 
distinct biological function.  The variable copy number of CCL3L1 (and CCL4L1) 
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is probably due to an association with a repeat unit which is highly susceptible 
to duplication.  
 
It has been reported that median CCL3L1 gene copy number differs in different 
population groups (Gonzalez et al., 2005), leading to the hypothesis that gene 
dose relative to the average in each population group influences HIV-1/AIDS 
susceptibility, rather than copy number per se.  Low CCL3L1 copy number is a 
major determinant of enhanced HIV-1 susceptibility in both mother-to-child and 
adult-to-adult infection (Gonzalez et al., 2005).  It has been further shown that 
the phenotype of deficient production of CCL3 (i.e. total production of CCL3 and 
CCL3L1) is associated with increased risk of intrapartum maternal-infant HIV-1 
transmission (Meddows-Taylor et al., 2006).  In addition, in HIV-1 infected 
adults, lower CCL3L1 gene copy numbers have been shown to be associated 
with an increased risk of rapid progression to AIDS or death (Gonzalez et al., 
2005).  A recently-published study has shown that variations in CCL3L1 gene 
copy number, together with CCR5 polymorphisms, influence the risk of HIV-1 
transmission and disease progression independently of HIV-1 viral load (Dolan 
et al., 2007). 
 
The first aim of this study was to determine median CCL3L1 gene copy 
numbers among HIV-1 uninfected adult South Africans within various population 
groups, and subgroupings within these groups.  Once population-specific 
median CCL3L1 copy numbers had been established, CCL3L1 copy numbers in 
HIV-1 infected Black South Africans were investigated.  
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In addition, CCL3L1 copy number polymorphisms were examined within the 
context of MTCT of HIV-1, with the aim of establishing whether lower CCL3L1 
gene copy numbers could be independently associated with transmission of 
HIV-1. 
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4.2 Results 
 
4.2.1 CCL3L1 copy number determination 
 
A real-time PCR assay to determine CCL3L1 gene copy number was 
established and optimised, based on a previously published method (Townson 
et al., 2002).  As additional confirmation of results obtained, those samples 
determined to have zero or single CCL3L1 gene copies pdg were further 
examined. 
 
Samples giving a result of zero CCL3L1 gene copies were confirmed using 
alternate PCR primers (A and B; Chapter 2.4.2) designed to amplify a different 
region of the CCL3 and CCL3L1 genes.  These primers amplify PCR products 
of approximately 1240 bp for CCL3 and 1550 bp for CCL3L1 (due to a 312 bp 
Alu element deletion within the 5’ region of CCL3 compared to CCL3L1), 
allowing for their separation using agarose gel electrophoresis (Figure 24). 
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Figure 24   
CCL3 (bottom band; 1240 bp) and CCL3L1 (top band; 1550 bp) PCR products. 
Lanes 1 and 8: 200 bp molecular weight markers; lanes 2-4: samples with 0 
copies of CCL3L1; lane 5: sample with 1 copy of CCL3L1; lane 6: sample with 8 
copies of CCL3L1; lane 7: PCR negative control. 
  
 
Samples giving a result of a single CCL3L1 gene copy pdg were confirmed by 
sequencing to ensure homozygosity.  Sequencing was performed using primers 
A and B described above, covering intron 1 (Chapter 2.4.2, Table 6), which 
contains SNPs known to be highly polymorphic within our study population (M. 
Paximadis, unpublished data).  An example of one such site is shown in Figure 
25; Samples 2 and 3 show a single peak at the position marked, demonstrating 
homozygous TT genotypes, while Sample 1 shows a double peak, 
demonstrating a heterozygous CT genotype. 
1kb 
1 2 3 4 5 6 8 7 
 88 
 
 
 
 
       
 
 
Figure 25   
Sequencing chromatograms showing heterozygosity (Sample 1; multiple copies 
of CCL3L1) and homozygosity (Samples 2 and 3; single copies of CCL3L1)  
at the highlighted position in the CCL3L1 gene. 
 
 
 
Sample 1 
Sample 2 
Sample 3 
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4.2.2 Median CCL3L1 copy numbers determined in South African 
populations 
 
Median CCL3L1 gene copy numbers have been shown to vary depending on 
the population studied (Gonzalez et al., 2005).  With this in mind, before any 
conclusions can be drawn from CCL3L1 copy number studies within South 
African population groups, it was important first to establish the extent of 
CCL3L1 copy number variation among different populations.  Individuals 
studied were from all cohorts described in Chapter 2.1.1, for whom both DNA 
was available and race group documented (HIV-TB coh1, MTCT and Eskom).  
11/829 (1.3%) of the DNA samples (10 from the MTCT cohort, 1 from the TB 
group of HIV-TB coh1) were inadequate for accurate copy number 
determination due to low DNA concentration and poor quality  (Chapter 2.3.3).   
 
In groups of all infection status, CCL3L1 copy number pdg was significantly 
different between Black (median 5, range 0-11) and Caucasian (median 2, 
range 0-6) individuals (P<0.001) (Figure 26).   
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Figure 26   
CCL3L1 gene copy numbers pdg amongst Black and Caucasian South African 
adults.   
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These data show that within the Black population of South Africa, significantly 
(P<0.001) more individuals (45.3%) have CCL3L1 copy numbers below their 
population-specific median than do Caucasian South Africans (22.7%) (Figure 
27). 
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Figure 27   
Black and Caucasian South African adults stratified on the basis of their 
CCL3L1 gene copy numbers pdg greater than, equal to, or less than their 
respective population-specific medians.   
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Population subgrouping data was available for individuals within the Eskom 
cohort (Chapter 2.1.3, Table 5).  Figure 28 shows these subgroups, along with 
groups of Caucasian and Black individuals for whom subgrouping data was 
unavailable (HIV-TB coh1 and MTCT), with Total Caucasian and Total Black 
groups.  Subgroups within each of the Total Caucasian and Total Black groups 
did not differ significantly from each other in median CCL3L1 copy number 
(P>0.05), supporting that population stratification need not be based on such 
subgroupings. 
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Figure 28   
Median CCL3L1 copy number pdg within South African populations and 
subgroups.   
Numbers within bars indicate the number of individuals in each group. 
Dark bars represent total groups, blue and green Caucasian and Black 
respectively; light bars represent subgroups, blue and green Caucasian and 
Black respectively.  
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4.2.3 CCL3L1 copy number within HIV-1 positive and negative 
populations 
 
Having established median CCL3L1 gene copy numbers for the South African 
population groups comprising our study cohorts, we next questioned whether 
CCL3L1 copy number plays a role in susceptibility to HIV-1 within the Black 
population.   
 
HIV-1 positive and HIV-1 negative groups have similar median CCL3L1 copy 
numbers (Figure 29); this was largely independent of study cohort (Figure 30). 
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Figure 29   
CCL3L1 gene copy numbers amongst HIV-1 positive and HIV-1 negative Black 
South African adults (from all cohorts with known HIV-1 status).   
Data are presented as medians (horizontal bar), 25th and 75th percentiles 
(boxes), 10th and 90th percentiles (bars), and outliers (o). 
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Figure 30   
CCL3L1 gene copy numbers amongst HIV-1 positive and HIV-1 negative Black 
South African adults, divided according to study cohort. 
Data are presented as medians (horizontal bar), 25th and 75th percentiles 
(boxes), and 10th and 90th percentiles (bars). 
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If the HIV-1 positive and negative groups of Black South Africans from the 
Eskom cohort were stratified according to CCL3L1 gene copy number, a non-
significant (P=0.838) trend towards lower copy number in HIV-1 positive 
individuals was seen, with a higher proportion of HIV-1 negative individuals 
(26% vs. 15% for HIV-1 positive individuals) having a CCL3L1 gene copy 
number greater than the population-specific median of 5 (P=0.340) (Figure 31). 
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Figure 31   
CCL3L1 gene copy numbers pdg amongst HIV-1 positive and HIV-1 negative 
Black South African adults from the Eskom cohort (a), and individuals from the 
same cohort grouped according to CCL3L1 gene copy number distribution 
around the population-specific median of 5 (b). 
a 
b 
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4.2.4 CCL3L1 copy number and mother-to-child transmission of 
HIV-1 
 
MTCT of HIV-1 provides a good model for the study of susceptibility or 
resistance to HIV-1, in that all infants born to HIV-1-infected mothers are known 
to have been exposed to HIV-1 infection during pregnancy and birth, and the 
levels of exposure (as quantified by viral load) can be determined. 
 
A deficient production of the CCL3 chemokine has been demonstrated in those 
infants who become infected with HIV-1 intrapartum; importantly, a similar 
deficiency (although not statistically significant) has been shown in their 
mothers (Meddows-Taylor et al., 2006).  This suggests that a genetic 
determinant may underlie this deficiency, leading us to question whether 
CCL3L1 gene copy number may play a role. 
 
Samples used in this section of the study were from the MTCT study cohort 
described in Chapter 2.1.2; 3 samples from the cohort of HIV-1 infected 
mothers and 3 from the infant cohort were insufficient for genotyping.  
 
There was no difference in median CCL3L1 copy number between HIV-1 
infected mothers (n=264) and their uninfected counterparts (n=13), although the 
number of uninfected controls was too low for accurate comparison. 
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When mothers transmitting HIV-1 to their infants were compared with non-
transmitting mothers, there was a trend towards reduced CCL3L1 copy number; 
however, this was not significant (P=0.099) (Figure 32). 
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Figure 32   
CCL3L1 copy numbers pdg in HIV-1 positive mothers comparing those that 
transmitted HIV-1 to their infants with those that did not. 
Data are presented as medians (horizontal bar), 25th and 75th percentiles 
(boxes), and 10th and 90th percentiles (bars). 
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However, when CCL3L1 copy numbers were examined in HIV-1-exposed 
infants, those who became infected with HIV-1 had significantly lower CCL3L1 
copy numbers (P=0.018) than those who remained uninfected (Figure 33).  
CCL3L1 copy numbers did not differ according to the timing of infection where 
this was known (whether intrapartum or in utero).  
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Figure 33   
CCL3L1 copy numbers pdg in infants born to HIV-1 positive mothers 
comparing those that became infected with those that did not, and comparing 
those HIV-1 positive infants known to have become infected intrapartum vs. in 
utero.   
Data are presented as medians (horizontal bar), 25th and 75th percentiles 
(boxes), and 10th and 90th percentiles (bars).  
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4.2.5 CCL3L1 copy number and plasma levels of CCL3 
 
CCL3L1 copy number has been related to ex vivo LPS-stimulated monocyte 
production of CCL3 (Townson et al., 2002), and to PHA-stimulated CCL3 
production in CBMCs of HIV-1-exposed uninfected infants and PBMCs of HIV-1 
infected mothers (Meddows-Taylor et al., 2006).  Cells from individuals with 
higher CCL3L1 gene copy numbers would therefore in general be expected to 
produce more CCL3 upon stimulation.  However, to date there have been no 
reports on how CCL3L1 gene copy number might relate to peripheral circulating 
levels of CCL3. 
 
Previously tested MTCT study cohorts have demonstrated lower peripheral 
levels of CCL3 at comparable CCL3L1 gene copy numbers in mothers 
transmitting HIV-1 to their infants intrapartum compared to those not 
transmitting HIV-1 (Meddows-Taylor et al., 2006), mirroring results from PHA-
stimulated PBMCs and deficient infant CCL3 production.  As seen in Chapter 3, 
circulating CCL3 levels are increased in the presence of HIV-1 infection.  
Understanding the relationship between CCL3L1 gene copy number and 
peripheral levels of CCL3 is therefore confounded by existing HIV-1 infection.  
For this reason, peripheral plasma CCL3 levels were examined in uninfected 
individuals (Caucasian and Black individuals from the control group of HIV-TB 
coh1), to assess the relationship between these levels and CCL3L1 gene copy 
number in population groups that we have shown to have significantly different 
CCL3L1 copy numbers. 
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We have shown (Chapter 3.3.1.1) that Black individuals within our control group 
tend to have lower peripheral blood levels of CCL3 than Caucasians.  Earlier in 
this Chapter we showed that Black individuals have significantly higher CCL3L1 
copy numbers than Caucasians.  Figure 34 shows the contrasting data for 
protein levels and CCL3L1 gene copy number in these two population groups. 
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Figure 34   
CCL3L1 gene copy number pdg (in blue) and plasma CCL3 levels (in orange) in 
uninfected Black and Caucasian individuals from the HIV-TB coh1 control 
group. 
Data are presented as medians (horizontal bar), 25th and 75th percentiles 
(boxes), 10th and 90th percentiles (bars) and extremes (*). 
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Within these population groups (in the HIV-TB coh1 control group), CCL3L1 
gene copy number was weakly correlated with plasma CCL3 levels in 
Caucasian individuals only (P=0.021) (Figure 35).  In contrast to what might be 
expected, among Black individuals, those with detectable plasma levels of 
CCL3 (n=11) did not present with higher CCL3L1 gene copy numbers when 
compared to those with undetectable CCL3 levels (n=38) (Figure 36).  
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Figure 35   
Scatter plot of plasma CCL3 levels against CCL3L1 gene copy number pdg in 
uninfected Caucasian and Black individuals from the HIV-TB coh1 control 
group. 
* correlation is significant at the 0.05 level (2-tailed) 
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Figure 36   
CCL3L1 gene copy number pdg in uninfected Black individuals from the HIV-TB 
coh1 control group, comparing those with detectable plasma CCL3 to those 
without. 
Data are presented as medians (horizontal bar), 25th and 75th percentiles 
(boxes) and 10th and 90th percentiles (bars). 
 
 
 
When Caucasian individuals from the control group of HIV-TB coh1 were 
stratified according to CCL3L1 gene copy number less than, equal to, or greater 
than the population-specific mean of 2, a trend towards increasing CCL3 
production with increasing CCL3L1 gene copy number was noted (Figure 37). 
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Figure 37   
CCL3 levels in plasma in uninfected Caucasian individuals from HIV-TB coh1 
control group grouped according to CCL3L1 gene copy number pdg distribution 
around the population-specific median of 2. 
Data (in red) are presented as medians (horizontal bar), 25th and 75th 
percentiles (boxes), 10th and 90th percentiles (bars) and extremes (*).  Black 
circles represent individual data points. 
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Plasma CCL3 levels in ART-naïve HIV-1 positive Black individuals from HIV-TB 
coh1 were examined, since HIV-1 infection provides an in vivo stimulus for 
increased chemokine production (Chapter 3.2.1.3, Figure 17).  No correlation 
with CCL3L1 gene copy number was evident, when either HIV-1 and HIV-1/TB 
groups together were studied (Figure 38), or the HIV-1 group alone was 
analysed (data not shown). 
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Figure 38   
Scatter plot of plasma CCL3 levels against CCL3L1 gene copy number pdg in 
HIV-1 infected Black individuals (ART-naïve) from the HIV-1 and HIV-1/TB 
groups within HIV-TB coh1. 
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4.3 Discussion 
 
Previously published results have shown that median copy numbers of the 
CCL3L1 gene differ depending on the population group studied (Gonzalez et 
al., 2005).  Our results agree with these findings, with figures for median 
CCL3L1 copy numbers in South African Caucasian and Black individuals (2 and 
5, respectively) matching the published data. These results highlight the 
importance of controlling for population grouping when undertaking genetic 
association studies and when attempting to understand the relationships 
between specific genetic determinants and phenotypic outcomes (based on 
immunological, transmission and disease progression data).   
 
Gonzalez et al. (Gonzalez et al., 2005) demonstrated a clear link between 
reduced CCL3L1 copy number and susceptibility to HIV-1 within their study 
cohorts (adults of European American, African American and Hispanic 
American descent, and Argentinean mothers and children); most importantly, 
the effects of reduced CCL3L1 copy number were relevant only when compared 
to the population-specific medians.  However, another study has been unable to 
show any correlation between CCL3L1 gene copy number and susceptibility to 
HIV-1 or progression to AIDS in a smaller cohort comprising mainly adolescent 
African Americans (Shao et al., 2007). 
 
We have demonstrated that more Black individuals (45.3%) in South Africa 
have lower CCL3L1 copy numbers than their population-specific median, 
compared to Caucasian individuals (22.7%), which according to the criterion 
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described by Gonzalez et al. (Gonzalez et al., 2005), would suggest that as a 
population more Black than Caucasian individuals may be at increased risk for 
acquiring HIV-1 infection (at least with respect to this particular factor). 
 
In Black mothers from antenatal clinics within Gauteng, we were unable to draw 
conclusions about any association between CCL3L1 gene copy numbers below 
median and susceptibility to HIV-1, due to the very low numbers of HIV-1 
uninfected controls from the MTCT group.  In Black adults from the Eskom 
cohort, we have shown a non-significant trend towards lower CCL3L1 gene 
copy numbers in HIV-1 positive individuals, but this requires further verification.  
It was not the intention of this study to address susceptibility to HIV-1 in adults, 
but rather to obtain some insight into the distribution of CCL3L1 gene copy 
numbers in our population for the design of future studies. 
 
It may prove to be the case that since individuals with lower CCL3L1 copy 
numbers seem to have a more rapid disease progression (Gonzalez et al., 
2005), they may have died earlier during the South African HIV-1/AIDS 
epidemic, which has only recently begun to be addressed with the roll-out of 
antiretroviral therapy.  It remains possible that our sample selection may show 
bias in that it does not comprise a random case controlled study.  Ideally, a 
prospective study cohort could be examined in which exposure to HIV-1 
infection is well-documented, such as sex workers or haemophiliacs.  It should 
however be noted that the risk of infection with HIV-1 varies with the route of 
infection (Table 9), which needs to be taken into account.  
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Table 9   
Risk of infection with HIV-1 depending on route of infection.  
(from (Cohen, 2004)) 
 
Route of infection Risk of infection 
Sexual transmission 
Female-to-male 
Male-to-female 
Male-to-male 
Fellatio 
 
1:700 to 1:3000 
1:200 to 1:2000 
1:10 to 1:1600 
0 to 6% 
Parenteral transmission 
Transfusion of infected blood 
Needle sharing 
Needle stick 
Needle stick / AZT PEP 
 
95:100 
1:150 
1:200 
1:10000 
MTCT 
Without AZT treatment 
With AZT treatment 
 
1:4 
< 1:10 
 
 
Of the infection routes described above, we directly addressed the question of 
the possible association of CCL3L1 gene copy number and maternal-infant HIV-
1 transmission.  HIV-1 positive mothers who transmitted HIV-1 to their infants 
(in utero or intrapartum) showed a trend towards lower CCL3L1 copy numbers 
compared to mothers who did not.  CCL3L1 gene copy numbers were however 
significantly reduced in those infants who became infected with HIV-1 
(regardless of the timing of transmission, i.e. in utero vs. intrapartum) compared 
with those infants exposed to HIV-1 who remained uninfected.  This 
demonstrated that the genetic factor(s) underlying MTCT of HIV-1 in our cohorts 
was primarily due to susceptibility of the infants that become infected rather 
than due to a transmissibility factor in their mothers.  Therefore, the trends 
noted amongst mothers were reflecting their genetic relatedness to their infants.  
These results have been published (Meddows-Taylor et al., 2006).  A further 
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extension of this current study (with larger numbers) has since demonstrated 
that higher infant CCL3L1 gene copy number is strongly associated with 
reduced susceptibility to HIV-1 only in the absence of maternal nevirapine (this 
association was attenuated at low maternal viral loads) (Kuhn et al., 2007). 
 
It is known that an increase in CCL3L1 gene copy number corresponds to an 
increase in cellular production of CCL3 chemokine, in both LPS-activated 
monocytes (Townson et al., 2002) and in PHA-stimulated PBMCs (Meddows-
Taylor et al., 2006); this led us to question whether a similar relationship might 
exist between CCL3L1 gene copy number and peripheral CCL3 levels in 
uninfected individuals (since the presence of HIV-1 infection serves as a 
confounder given that circulating CCL3 levels are increased, and are likely to be 
affected by stage of disease progression). 
 
There are clear and contrasting differences in median CCL3L1 copy number 
and circulating levels of CCL3 between uninfected South Africans of Black or 
Caucasian descent – higher median copy number in Black groups did not 
correspond to higher peripheral levels of chemokine product, which suggests 
that the Black population may be even more at risk for HIV-1 infection than 
would be suggested by CCL3L1 copy number data alone, if circulating levels of 
CCL3 are indeed a meaningful measure of likely susceptibility.  In contrast, 
within the Caucasian uninfected individuals, the expected trend towards 
increased CCL3 production at CCL3L1 gene copy numbers greater than the 
population-specific median of 2 was clearly evident.  These latter findings 
provide evidence that increased circulating levels of CCL3 do relate to 
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increased CCL3L1 copy number, but this would likely only apply to populations 
with largely detectable levels of this chemokine. 
 
Genetic factors contributing to changes in CCL3 regulation, in terms of 
polymorphisms within chemokine genes themselves, or in other genes 
controlling chemokine production, remain to be elucidated.  It is likely that copy 
number per se will not prove to be the only factor controlling CCL3 production 
and therefore susceptibility to HIV-1, but that polymorphisms within both active 
genes (CCL3 and CCL3L1) may also play a role, along with polymorphisms in 
the genes of other factors that may be involved in the regulation of expression 
of the CCL3 chemokine.  For this reason, further analysis of SNPs within the 
CCL3 and CCL3L1 genes, together with an investigation of CCL3 and CCL3L1 
gene expression patterns within our study cohorts would be of great interest for 
future studies. 
 
Factors other than those with a genetic basis that can impact on levels of CCL3 
in vivo include (i) infectious agents, for example HTLV-2 (Pilotti et al., 2007) and 
hepatitis G (GBV-C) (Xiang et al., 2004), both of which increase CCL3 levels, 
and (ii) the maturation state of the immune system.  In the latter regard, infants 
are known to produce higher levels of CCL3 than adults, despite no differences 
in CCL3L1 gene copy number (Tiemessen & Kuhn, 2006).  These points further 
highlight the complex nature of the regulation of chemokine production.   
 
Findings using the maternal-infant HIV-1 transmission model (Meddows-Taylor 
et al., 2006) suggest that it is the abundance of CCL3 upon initial encounter 
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with HIV-1 that may be important in protection vs. susceptibility in infants, in that 
infants with deficient ex vivo cord blood cell production of CCL3 were 
susceptible to HIV-1 infection.  The levels of CCL3 may be key to the 
development of an effective innate immune response (including the 
inflammatory process) and subsequent adaptive immune responses 
(Tiemessen & Kuhn, 2007), and repeated exposure to HIV-1 may provide a 
“booster effect” on acquired immune responses developed in response to HIV-1 
encounter.   
 
It remains to be established how circulating levels of CCL3 compare to 
unstimulated or PHA-stimulated production for the same individuals (for 
example uninfected Black and Caucasian individuals), and how these measures 
compare to CCL3L1 gene copy number and mRNA expression.  Understanding 
these relationships is central to our understanding of how this important 
chemokine is produced and regulated in different population groups and in 
different individuals within these groups.   
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CHAPTER 5 
 
IL8-251T→A POLYMORPHISM AND SUSCEPTIBILITY TO TB 
IN SOUTH AFRICANS 
 
 
5.1 Introduction 
 
There is a common single nucleotide polymorphism (SNP), located 251 bp 
upstream of the IL8 transcription start site (IL8-251T→A), which affects CXCL8 
expression in response to LPS stimulation of whole blood (Hull et al., 2000).  
Hull et al. (Hull et al., 2000) demonstrated that CXCL8 production in whole 
blood (from healthy donors in the United Kingdom) on stimulation with LPS was 
greatest in AA homozygotes, then AT heterozygotes, with lowest production in 
TT homozygotes.  This SNP may not be a functional change in itself, since it is 
located upstream of the promoter binding sites for transcription factors (Ma et 
al., 2003), but may lie in linkage disequilibrium with the functional variant (Hull 
et al., 2001). 
 
It has been suggested that increased expression of CXCL8, related to the IL8-
251A allele, may attract an excess of leukocytes to the site of Mtb infection, 
causing extensive tissue damage and increasing the risk of severe vs. latent TB 
(Ma et al., 2003). 
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Given these findings, we hypothesised that the IL8-251T→A SNP may be 
contributing to the TB epidemic in South Africa, so this was a preliminary study 
which aimed to investigate the prevalence of the IL8-251A allele within different 
South African population groups.   
 
In addition, we aimed to compare the prevalence of this allele (known to be 
associated with differences in CXCL8 expression and susceptibility to Mtb 
infection) between groups comprising uninfected controls, individuals who are 
singly infected with HIV-1 or Mtb, and individuals coinfected with HIV-1 and Mtb. 
 
With these aims in mind, the first objective was to develop a real-time PCR-
based assay for analysis of the IL8-251T→A SNP. 
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5.2 Results 
 
DNA samples used in this section of the study were selected from the following 
groups (for details of study cohorts, refer to Chapter 2.1):  
 
(1) Caucasian adults (HIV-1 negative n=88) from the Eskom study cohort 
(English n=44, Afrikaans n=44). 
(2) Black HIV-1 positive adults (total n=135) from the MTCT cohort (n=70), 
Eskom cohort (Xhosa n=4, Zulu n=12) and HIV-1/TB individuals from 
HIV-TB coh1 (n=49). 
(3) Black HIV-1 negative adults (total n=113) from the Eskom cohort (Venda 
n=2, Xhosa n=42 Zulu n=43) and TB individuals from HIV-TB coh1 
(n=26).   
 
Where sample numbers are lower than the total number of samples in each 
cohort, this reflects the fact that this section of the project is designed as a 
preliminary study simply to assess the variation in the IL8-251T→A SNP within 
South African populations.   
 
 
5.2.1 IL8-251T→A SNP real-time PCR 
 
We first tested the published method (Hull et al., 2000) for determination of the 
IL8-251T→A polymorphism.  This involved PCR amplification using 2 sets of 
primers designed to amplify separately the IL8-251T and IL8-251A alleles 
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(Chapter 2.5.1), followed by detection of the 347 bp PCR products by agarose 
gel electrophoresis (Figure 39).  This method was then optimised for high-
throughput using the Electro-Fast Stretch 108 Gel Tank System, but was still 
not conducive to rapid high-throughput screening (Figure 40).  For this reason, 
a real-time PCR-based method was developed which would allow rapid and 
accurate SNP determination. 
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Figure 39   
2% agarose gel showing IL8-251A and IL8-251T PCR products. 
Lanes 1 and 10: standards (100 bp DNA ladder); lanes 2 and 6: AA 
homozygous; lanes 3 and 7: AT heterozygous; lanes 4 and 8: TT homozygous; 
lanes 5 and 9: negative controls. 
 
347bp 
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Figure 40   
2% agarose gels showing IL8-251A and IL8-251T SNP PCRs run on the high-
throughput Electro-Fast Stretch 108 Gel Tank System.   
Samples were amplified using T-allele and A-allele specific primers and run in 
corresponding lanes on parallel agarose gels.  E.g. lane 1=AA, lane 2=AT, lane 
33=TT.  Standards: 100 bp DNA ladder (†) and PCR positive control (‡). 
 
‡ † 
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Real-time PCR results take the form of amplification plots, which allow rapid 
and simple assignment of genotypes (homozygous AA or TT, or heterozygous 
AT) (Figure 41).  Figures show the point during PCR amplification at which 
fluorescence (due to incorporation of SYBR Green into double-stranded PCR 
products) rises above background levels, indicating the presence of target 
sequence.  The apparent presence of low concentrations of the opposite allele 
in homozygous individuals indicates a low degree of cross-priming which can be 
clearly distinguished from a true positive. 
 
Each PCR reaction can be checked by dissociation curve analysis to ensure 
single specific PCR product amplification (Figure 42).  Samples are heated to 
95°C to denature double-stranded DNA, then annealed slowly.  Single PCR 
product (indicating specific PCR reactions) shows a single peak indicating the 
temperature at which SYBR Green (which binds only double-stranded DNA) 
becomes incorporated.   
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Figure 41   
Amplification plots showing IL8-251T and IL8-251A real-time PCRs. 
(a) AA homozygous, (b) AT heterozygous, (c) TT homozygous, (d) negative 
control.   
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Figure 42   
Dissociation curves showing single PCR products for IL8-251T and A real-time 
PCRs.   
 
 
To test the sensitivity and efficiency of the real-time PCR method, 90 samples 
which included representatives of each variation (i.e. AA homozygous, AT 
heterozygous and TT homozygous) were run in parallel using both the 
conventional agarose gel and real-time methods.  In each case exact 
concordance was achieved, demonstrating the high specificity of the real-time 
method; the sensitivity of the real-time PCR method was superior to the 
agarose gel-based method in that samples which produced no visible PCR 
bands on agarose (9/90 samples; 10%) were successfully amplified by real-time 
PCR. 
A T 
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Using the real-time PCR method, 96 samples can be analysed in less than 2 
hours, compared to a minimum of 4 hours using agarose-gel based systems, 
and with a dramatic reduction in manual operations. 
 
 
5.2.2 Genotype and population group 
 
We first addressed the question of whether population groups within South 
Africa showed differing proportions of the IL8-251T→A genotype, as this has 
the potential to influence susceptibility to TB, which is known to comprise a 
significant health risk in South Africa.  Ma et al. (Ma et al., 2003) have shown 
that AA homozygosity was linked to an increased risk of TB compared to TT 
homozygosity, with AT heterozygosity linked to an intermediate risk.  For this 
reason, we examined both the frequency of the A allele in groups, as well as the 
frequency of heterozygosity vs. homozygosity.   
 
Among Caucasian individuals, significantly greater proportions of AT (44%; 
P=0.005) and TT (36%; P<0.001) compared to AA (19%) genotypes were 
found, while among Black individuals, there was a greater proportion of AA 
(71%; P<0.001) than AT (27%) and TT (2%) genotypes (Figure 43a).  These 
proportions were independent of population subgrouping (Figure 43b).  In 
addition, IL8-251T or A alleles were significantly associated with population 
group, with Caucasian individuals showing a greater proportion of T alleles 
(59%), and Black individuals a greater proportion of A alleles (85%; P<0.001) 
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(Figure 44a).  These proportions did not change significantly if population 
groups were broken down into subgroupings as indicated (P>0.05) (Figure 
44b).   
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Figure 43   
Percentages of IL8-251T→A genotype in study populations (a) and in 
population subgroups (b). 
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Figure 44   
Percentages of IL8-251 alleles in study populations (a) and in population 
subgroups (b). 
(x alleles = 2n individuals) 
 
 
 
5.2.3 Genotype and TB status 
 
Having demonstrated that Black South Africans have very high proportions of 
the IL8-251A allele, potentially increasing their risk for severe TB, we next 
examined this allele in the context of Mtb infection in Black South Africans, 
firstly as a single group, and then stratified on the basis of HIV-1 infection. 
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There was no statistically significant difference between proportions of 
individuals with either the IL8-251T→A genotypes or IL8-251 alleles in TB 
positive and negative groups within the Black population, regardless of HIV-1 
status (P>0.05) (Figure 45a and b). 
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Figure 45   
Percentages of (a) IL8-251T→A genotypes and (b) IL8-251 alleles in TB 
positive and negative Black individuals stratified according to HIV-1 status. 
(x alleles = 2n individuals) 
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5.2.4 Genotype and HIV-1 status 
 
With the IL8-251A genotype showing no association with TB infection in our 
study cohort, we next examined it within the context of HIV-1 infection, both as 
a group and then specifically within those HIV-1 positive patients coinfected with 
TB.  
 
There was no statistically significant difference between proportions of 
individuals with either the IL8-251T→A genotypes or IL8-251 alleles in HIV-1 
positive and negative groups within the Black population, regardless of TB 
status (P>0.05) (Figure 46a and b). 
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Figure 46   
Percentages of (a) IL8-251T→A genotypes and (b) IL8-251 alleles in HIV-1 
positive and negative Black individuals stratified according to TB status. 
(x alleles = 2n individuals) 
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5.2.5 Genotype and peripheral CXCL8 levels 
 
Given the very small numbers of samples showing detectable plasma CXCL8 
levels (n=1/17 of the HIV-1 group, n=1/27 of the TB group, and n=10/61 of the 
HIV-1/TB group), most of which were from HIV-1/TB coinfected individuals 
(Chapter 3.2.1.3, Figure 17e), we could not address the relationship between 
circulating levels of CXCL8 and the IL8-251T→A genotype. 
 
 
5.3 Discussion 
 
The IL8-251A allele has been shown to be present in European (United 
Kingdom) and African (The Gambia) individuals at frequencies of 0.47 and 0.89, 
respectively (Hull et al., 2001), and in White American and African American 
individuals at 0.37 and 0.75, respectively (Ma et al., 2003).  In South African 
population groups, a similar pattern was seen, with IL8-251A allele frequencies 
of 0.41 for Caucasian groups, and 0.85 for Black groups.  The differences in 
allele distribution between population groups suggest that selection pressure 
may have been a factor at this locus during human evolution. 
 
Published data have shown an association between the IL8-251T→A genotype 
and risk for severe TB infections in HIV-1 seronegative TB patients (106 White 
and 188 African American individuals), with control HIV-1 negative, TB negative 
groups (107 White and 167 African American individuals) (Ma et al., 2003).  Our 
study was not powered to address this question, but we nonetheless stratified 
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Black individuals on the basis of known disease outcomes.  As expected, no 
associations could be seen.  With so few Black individuals within our study 
cohort that are homozygous TT (n=4/248; 2%), and no TT homozygous 
individuals with TB alone (out of 26 Black TB patients) a far larger cohort would 
be needed to show disease associations.   
 
The possibility remains that the sheer magnitude of the TB epidemic in this 
country, and the large majority of the IL8-251A allele seen in the population 
group at greatest risk of acquiring TB, have combined to overwhelm any such 
genetic predisposition.  In addition, South Africa has one of the largest HIV-1 
epidemics in the world, and HIV-1 is a major risk factor for acquiring TB; the 
study linking TB to the IL8-251T→A polymorphism was limited to HIV-1 
seronegative TB patients and controls, whereas it is becoming increasingly 
difficult in South Africa to obtain prospective samples from HIV-1 negative TB 
patients. 
 
In addition, changes in CXCL8 levels dependent on the IL8-251T→A 
polymorphism have been demonstrated only in LPS-stimulated whole blood, 
rather than as circulating levels determined in plasma (Hull et al., 2000).  
Whether a similar relationship might exist between CXCL8 circulating levels and 
genotype is unknown.  In our study, there were too few DNA samples with 
corresponding plasma samples which had detectable levels of CXCL8 to allow 
for a comparison of peripheral blood CXCL8 levels with genotype.  Further 
studies on large numbers of individuals with TB only (preferably at the time of 
acute TB infection, prior to the commencement of antituberculosis therapy), that 
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include determining CXCL8 levels in stimulated PBMC culture supernatants and 
comparison with genotyping data at the IL8-251 locus, would enable testing of 
the hypothesis that changes in allele frequency (within a population group) 
affect susceptibility to TB, due to their impact on changes in CXCL8 levels. 
 
Future studies would benefit from including a population group in South Africa 
not studied to date with respect to the IL8-251T→A genotype, namely those of 
mixed ancestry.  The so-called “Coloured” communities in the Western Cape of 
South Africa are at extremely high risk of TB (Berman et al., 1992), and studies 
of the proportions of IL8-251T→A genotypes within these groups could shed 
greater light on the subject.  In a population of mixed ancestry a greater 
proportion of T alleles should be present (compared to Black population 
groups), which would allow any association of the IL8-251T→A SNP with 
susceptibility to TB to be more easily studied. 
 
The IL8-251A allele is significantly more prevalent amongst Black individuals, 
both those infected with HIV-1 and/or TB and those uninfected, than amongst 
Caucasian individuals.  Given the data linking TB susceptibility to this allele (Ma 
et al., 2003), this suggests that South African Black population groups are 
genetically predisposed to be at greater risk for TB, as seems to be borne out 
by the demographics of the TB epidemic.  TB demographics are of course 
complicated by other factors, including (but not limited to) socio-economics and 
polymorphisms in other genes, neither of which has been taken into account in 
this study. 
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There are many factors, both genetic and environmental, which contribute to 
susceptibility to both Mtb and HIV-1, and which clearly need to be considered 
within each population group individually.  CXCL8 is one of these factors which 
no doubt influences both susceptibility to and progress of TB disease, but which 
cannot be considered in isolation as a means of determining groups at risk. 
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CHAPTER 6 
 
CONCLUDING REMARKS 
 
 
The regulation of chemokine levels is of paramount importance in the 
development of protective immunity to infectious disease.  We have focussed 
on those chemokines (CCL3, CCL4, CCL5, CXCL8 and CXCL12) known to play 
an important role in the pathogenesis of HIV-1 and TB, which together pose the 
largest public health challenge in South Africa. 
 
CCL3 has generated much interest recently in the literature as a major 
determinant of susceptibility to HIV-1 and AIDS.  We have shown that in Black 
South African adults, higher numbers of CCL3L1 gene copies are not linked to 
correspondingly higher plasma CCL3 levels, implying the presence of other 
genetic polymorphisms which may result in lowered gene expression (in 
contrast to Caucasian individuals, in whom CCL3L1 gene copy number higher 
than the population-specific median does correspond to higher CCL3 
production).  This, coupled to the finding that more Black individuals have 
CCL3L1 gene copy numbers lower than their population-specific median, 
suggests that Black South Africans may be at a particularly high risk for 
acquiring HIV-1 (at least with respect to this factor).  The high rate of HIV-1/TB 
coinfection in South Africa may serve to exacerbate this problem. 
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We have demonstrated that a polymorphism within the IL8 gene (encoding 
CXCL8), which has been shown to be linked to susceptibility to TB (in White 
and African American individuals), is far more prevalent within Black South 
African individuals than in Caucasians.  This suggests that if the IL8-251T→A 
polymorphism is found to be linked to TB susceptibility in South African 
populations, South African Black individuals may be genetically predisposed to 
be at greater risk for infection with Mtb.   
 
There are many factors, both genetic and environmental, which contribute to 
susceptibility to both Mtb and HIV-1, and which clearly need to be considered 
within each population group individually.  Further studies should investigate 
larger cohorts (to include all groups available) to examine any possible 
differences in chemokine levels and genetic polymorphisms more closely. 
 
Future studies, besides including larger study cohorts, would benefit from an 
investigation into other polymorphisms (within the genes encoding these 
chemokines) known to affect chemokine production.  In addition, in vitro 
expression studies to characterise the polymorphisms we have studied would 
improve our understanding of genotype-phenotype relationships. 
 
Only once we have gained an understanding of the host response to infection, 
and the mechanisms by which innate and acquired immunity are generated 
(and, most importantly, the reasons for failure of the immune system to mount 
an effective response), can scientifically appropriate interventions be designed 
to combat infections such as HIV-1 and TB.  A “one size fits all” approach may 
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be of little use, since we have demonstrated that different individuals do not 
necessarily have identical immune responses to the same pathogens.  An 
understanding of the effects of host genotype will be key in the design of 
efficient therapies and prevention strategies, which are so desperately needed.   
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Appendix A 
Abbreviations 
 
 
AIDS Acquired Immune Deficiency Syndrome 
ART antiretroviral therapy 
BCG Bacille Calmette-Guerin 
bp base pairs  
BSA bovine serum albumin 
CBMCs cord-blood mononuclear cells  
CNP copy number polymorphism 
CO2 carbon dioxide 
DC dendritic cell 
dH2O distilled water 
DNA deoxyribonucleic acid 
dNTP deoxynucleotide triphosphate 
EDTA  ethylenediaminetetraacetic acid 
ELISA enzyme-linked immunosorbent assay 
EST expressed sequence tag  
EtOH ethanol  
EU exposed-uninfected  
FAM 6-carboxyfluorescein 
GPCR guanosine nucleotide-protein-coupled receptor 
HAART highly active antiretroviral therapy 
HIV-1 Human Immunodeficiency Virus type 1 
HRP horseradish peroxidase  
HTLV-2 human T-lymphotropic virus 
IFN-γ interferon gamma 
IL-8/CXCL8 interleukin-8  
IP intrapartum  
IU in utero  
LPS lipopolysaccharide 
LTNP long-term non-progressor 
MDR-TB multi-drug resistant tuberculosis 
MgCl2  magnesium chloride 
MIP-1α/CCL3 macrophage inflammatory protein-1 alpha 
MIP-1β/CCL4 macrophage inflammatory protein-1 beta 
ml millilitre 
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mM millimolar 
Mtb Mycobacterium tuberculosis 
MTCT mother-to-child transmission  
NaOAc sodium acetate  
ng nanogram 
NK natural killer cell 
nM nanomolar 
NSI non-syncitia-inducing 
NVP nevirapine  
PAMP pathogen-associated molecular pattern 
PBMC peripheral blood mononuclear cell 
PBS phosphate-buffered saline 
PCR  polymerase chain reaction 
pdg per diploid genome  
pg picogram 
PHA phytohaemagglutinin 
PMNL polymorphonuclear leukocyte  
pmol picomole 
PMTCT prevention of mother-to-child transmission  
PRR pattern recognition receptor 
RANTES/CCL5 regulated upon activation, normal T-cell expressed, and secreted  
ROMA representational oligonucleotide microarray analysis 
RPMI medium Roswell Park Memorial Institute medium 
RSV respiratory syncytial virus  
SDF-1α/CXCL12 stromal cell-derived factor-1 
SI syncitia-inducing 
SIV Simian Immunodeficiency Virus 
SNP single nucleotide polymorphism  
STD sexually-transmitted disease 
TAMRA carboxytetramethyl-rhodamine 
TB tuberculosis 
TBE Tris/Borate/EDTA 
Th T-helper cell 
TLR Toll-like receptor 
TNF-α tumor necrosis factor alpha 
U units 
WHO World Health Organisation 
XDR-TB extremely/extensively drug resistant tuberculosis 
µg microgram 
µl microlitre 
µM micromolar 
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Appendix B 
Chemokine nomenclature 
 
 
(from http://en.wikipedia.org/wiki/Chemokine) 
 
CC chemokines 
 
Name Gene Other name(s) 
CCL1 Scya1 I-309, TCA-3 
CCL2 Scya2 MCP-1 
CCL3 Scya3 MIP-1α 
CCL4 Scya4 MIP-1β 
CCL5 Scya5 RANTES 
CCL6 Scya6 C10, MRP-2 
CCL7 Scya7 MARC, MCP-3 
CCL8 Scya8 MCP-2 
CCL9/CCL10 Scya9 MRP-2, CCF18, MIP-1γ 
CCL11 Scya11 Eotaxin 
CCL12 Scya12 MCP-5 
CCL13 Scya13 MCP-4, NCC-1, Ckβ10 
CCL14 Scya14 HCC-1, MCIF, Ckβ1, NCC-2 
CCL15 Scya15 Leukotactin-1, MIP-5, HCC-2, NCC-3 
CCL16 Scya16 LEC, NCC-4, LMC, Ckβ12 
CCL17 Scya17 TARC, dendrokine, ABCD-2 
CCL18 Scya18 PARC, DC-CK1, AMAC-1, Ckβ7, MIP-4 
CCL19 Scya19 ELC, Exodus-3, Ckβ11 
CCL20 Scya20 LARC, Exodus-1, Ckβ4 
CCL21 Scya21 SLC, 6Ckine, Exodus-2, Ckβ9, TCA-4 
CCL22 Scya22 MDC, DC/β-CK 
CCL23 Scya23 MPIF-1, Ckβ8, MIP-3, MPIF-1 
CCL24 Scya24 Eotaxin-2, MPIF-2, Ckβ6 
CCL25 Scya25 TECK, Ckβ15 
CCL26 Scya26 Eotaxin-3, MIP-4α, IMAC, TSC-1 
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CCL27 Scya27 CTACK, ILC, Eskine, PESKY, skinkine 
CCL28 Scya28 MEC 
 
 
CXC chemokines 
 
Name Gene Other name(s) 
CXCL1 Scyb1 Gro-α, GRO1, NAP-3 
CXCL2 Scyb2 Gro-β, GRO2, MIP-2α 
CXCL3 Scyb3 Gro-γ, GRO3, MIP-2β 
CXCL4 Scyb4 PF-4 
CXCL5 Scyb5 ENA-78 
CXCL6 Scyb6 GCP-2 
CXCL7 Scyb7 NAP-2, CTAPIII, β-Ta, PEP 
CXCL8 Scyb8 IL-8, NAP-1, MDNCF, GCP-1 
CXCL9 Scyb9 MIG, CRG-10 
CXCL10 Scyb10 IP-10, CRG-2 
CXCL11 Scyb11 I-TAC, β-R1, IP-9 
CXCL12 Scyb12 SDF-1, PBSF 
CXCL13 Scyb13 BCA-1, BLC 
CXCL14 Scyb14 BRAK, bolekine 
CXCL15 Scyb15 Lungkine, WECHE 
CXCL16 Scyb16 SRPSOX 
CXCL17 VCC-1 DMC, VCC-1 
 
 
C chemokines 
 
Name Gene Other name(s) 
XCL1 Scyc1 Lymphotactin α, SCM-1α, ATAC 
XCL2 Scyc2 Lymphotactin β, SCM-1β 
 
 
CX3C chemokines 
 
Name Gene Other name(s) 
CX3CL1 Scyd1 Fractalkine, Neurotactin, ABCD-3 
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Appendix C 
Cytokines involved in HIV-1 infection 
 
 
(from (Alfano & Poli, 2005)) 
 
Cytokine/chemokine Producer cell Effect on HIV infection/replication 
IL-2 Activated T cells, mDC Upregulation via induction of pro-
inflammatory cytokines 
IL-4 Activated T cells, Th2 
cells 
Bimodal: inhibition of cytokine-mediated virus 
replication (monocytes); enhancement of HIV 
expression (macrophages) 
IL-7 Epithelial cells Enhancement of HIV transcription 
IL-10 DC, activated T cells Bimodal: inhibition of cytokine-mediated virus 
replication (macrophages); enhancement of 
HIV transcription 
IL-12 MDC, APC Enhancement of HIV replication (PBMC) 
IL-13 Macrophages Post-transcriptional inhibition of HIV 
replication (macrophages) 
IL-15 Macrophages, PDC, 
NK 
Upregulation via induction of pro-
inflammatory cytokines 
IFN-α/β Monocytes, 
macrophages, PDC 
Inhibition of multiple steps of virus life cycle 
IFN-γ NK, NKT, γδT, CTL, 
PDC, activated T cells, 
Th1 cells 
Bimodal: enhancement of HIV transcription; 
inhibition of R5 virus entry and virion release 
TGF-β Hemopoietic & 
endothelial cells, 
connective tissue, 
macrophages, Th3 cells 
Bimodal: enhancement and suppression of 
HIV replication as a function of time of 
stimulation vs. infection (macrophages) 
CCL3, CCL4, CCL5 NK, DC, γδ, activated T 
cells, macrophages 
Inhibition of R5 virus entry 
CCL2 Monocytes, 
macrophages 
Enhancement of HIV replication 
CXCL8 Monocytes, activated T 
cells, NK, fibroblasts, 
endothelial & epithelial 
cells 
Enhancement of HIV replication 
 155 
Appendix D 
Genes involved in resistance to HIV-1/TB 
 
 
Genetic polymorphisms involved in resistance/susceptibility to HIV-1. 
 
Gene Polymorphism Effect on infection with HIV Ref 
CCL2-CCL7-
CCL11 gene 
cluster 
H7 haplotype Higher frequency in multiply-exposed 
uninfected individuals 
(Modi et al., 
2003) 
CCL3L1 
Copy number < 
pop.-specific 
average 
Susceptibility (Gonzalez et 
al., 2005) 
G590A Higher incidence in HIV+ (Colobran et 
al., 2005) 
CCL4L1 
SCYA4*L2 Susceptibility (Colobran et 
al., 2005) 
-28G Slow disease progression (Liu et al., 1999) 
-403A Increased frequency of infection (An et al., 2002) 
In1.1C Increased frequency of infection; 
rapid disease progression 
(An et al., 
2002) 
CCL5 
3’ 222C Increased frequency of infection (An et al., 2002) 
CCR2 V64I Delayed onset of AIDS (Smith et al., 1997) 
∆32 (het) Slow disease progression 
(Samson et al., 
1996), (Dean 
et al., 1996) 
∆32 (hom) Protection against infection 
(Liu et al., 
1996), (Dean 
et al., 1996) 
CCR5 
CCR5P1 (hom) Rapid progression to AIDS (Martin et al., 1998) 
Delayed onset of AIDS (Winkler et al., 1998) 
CXCL12 SDF1-3’A (hom) Accelerated progression (late-stage 
AIDS) 
(Brambilla et 
al., 2000) 
CX3CR1 I249/M280 (hom) Rapid progression to AIDS 
(Faure et al., 
2000) 
CXCR1 CXCR1-Ha Protects against rapid progression to AIDS 
(Vasilescu et 
al., 2007) 
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DCSIGN -336T→C Higher risk for parenteral HIV infection 
(Martin et al., 
2004) 
Heterozygosity Delayed onset of AIDS (Carrington et 
al., 1999) 
HLA-B*35 Rapid progression to AIDS 
(Carrington et 
al., 1999), 
(Gao et al., 
2005) 
HLA-Cw*04 Rapid progression to AIDS 
(Carrington et 
al., 1999), 
(Gao et al., 
2005) 
HLA-B57 Slow disease progression (Gao et al., 2005) 
HLA class I 
HLA-B27 Delayed onset of AIDS (Gao et al., 2005) 
IFNG -179T Rapid progression to AIDS (An et al., 2003) 
-592A Increased risk of infection; rapid progression to AIDS 
(Shin et al., 
2000) 
IL10 
-592C/C Long term non-progression (Shin et al., 2000) 
IL4R V50 (hom) Slow disease progression (Soriano et al., 2005) 
with HLA-B 
Bw4-80Ile Delayed progression to AIDS 
(Martin et al., 
2002) 
KIR3DS1 
without HLA-B 
Bw4-80Ile Rapid progression to AIDS 
(Martin et al., 
2002) 
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Genes and polymorphisms tested for association with TB and other 
mycobacterial diseases. 
 
Gene Polymorphism Population 
studied Disorder Effect of polymorphism Ref 
2q33-q37 (incl. 
NRAMP1) markers Mexican TB/Lsh/leprosy no linkage 
(Shaw et al., 
1993) 
5q (incl. IL4, 
IL5, IL9, IRF1, 
CD14) 
microsatellite Brazilian TB/Lsh/leprosy 
no linkage; linkage to 
ability to mount immune 
response to 
mycobacterial antigens 
(Blackwell et 
al., 1997) 
17q (incl. 
NOS2A, 
SCYA2-5) 
microsatellite Brazilian TB linkage (Blackwell et 
al., 1997) 
17q (NOS2A, 
CCL18, CCL4, 
STAT5B) 
SNPs Brazilian TB/leprosy linkage (Jamieson et 
al., 2004) 
-871G S African TB protection (Barreiro et 
al., 2006) CD209 
(encodes DC-
SIGN)  
-336A S African TB protection (Barreiro et 
al., 2006) 
CXCR1&2  White & AfrAm TB 
no significant 
associations 
(Ma et al., 
2003) 
FUT-2 SNP Gambian TB no association (Bellamy et 
al., 1998a) 
HLA-DQ  leprosy 
associated with multi-
bacillary lepromatous 
forms 
(Lagrange & 
Abel, 1996) 
HLA-DQA S Indian TB no association (Sanjeevi et 
al., 1992) 
HLA-DQB S Indian TB no association (Sanjeevi et 
al., 1992) 
DQB1*0503 Cambodian TB associated with 
susceptibility 
(Goldfeld et 
al., 1998) 
HLA-DR  leprosy associated with protective response 
(Lagrange & 
Abel, 1996) 
HLA-DRB S Indian TB no association (Sanjeevi et 
al., 1992) 
  TB susceptibility (Singh et al., 1983) 
HLA 
HLA-DR2 
  leprosy 
susceptibility to 
tuberculoid leprosy (not 
lepromatous) 
(van Eden et 
al., 1980) 
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HLA-B52 Indian pulmonary TB protective 
(Vijaya 
Lakshmi et 
al., 2006) 
HLA-B51 Indian pulmonary TB susceptibility 
(Vijaya 
Lakshmi et 
al., 2006) 
Brazilian leprosy association (Blackwell et 
al., 1997) 
Brazilian leishmaniasis weak association (Blackwell et 
al., 1997) microsatellite 
Brazilian TB no association (Blackwell et 
al., 1997) 
HLA complex 
(incl. TNFA/B 
haplotype 
HLA/TNF   TB 
association with 
protection & 
susceptibility to relapse 
(Selvaraj et 
al., 2001) 
Hp 
(haptoglobin) Hp1 & 2 Zimbabwe TB 
equal susceptibility; 
Hp2-2 higher risk of 
mortality 
(Kasvosve et 
al., 2000) 
Spanish TB 
A allele ↑ risk of TB; AA 
homozygotes ↓ 
stimulated prodn of 
IFN- γ 
(Lopez-
Maderuelo et 
al., 2003) IFNG +874T/A 
S African TB T allele over-
represented in controls 
(Rossouw et 
al., 2003) 
(CA)n intron 6 Croatian TB weak association (Fraser et al., 2003) 
IFNGR1 
inactivating 
mutations   mycobacteria 
↑ susceptibility in 
homozygous children (Hill, 1998) 
IL1A microsatellite Gambian TB marginal assoc (Bellamy et 
al., 1998a) 
SNP Gambian TB no association (Bellamy et 
al., 1998a) 
-511 Cambodian TB no association (Delgado et 
al., 2002) IL1B 
3953 Cambodian TB no association (Delgado et 
al., 2002) 
minisatellite Gambian TB marginal assoc (Bellamy et 
al., 1998a) 
IL1RA 
intron 2 tandem 
repeats Cambodian TB no association 
(Delgado et 
al., 2002) 
IL8  -251A White & AfrAm TB 
homozygosity 
associated with TB 
(Ma et al., 
2003) 
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Caucasian RSV 
associated with disease 
severity (IL-8 
production by LPS-
stimulated blood) 
(Hull et al., 
2000) 
SNP Gambian TB no association (Bellamy et 
al., 1998a) 
microsatellite Gambian TB no association (Bellamy et 
al., 1998a) 
-1082 Cambodian TB heterozygosity assoc 
with susceptibility 
(Delgado et 
al., 2002) 
-819 Cambodian TB no association (Delgado et 
al., 2002) 
-592 Cambodian TB no association (Delgado et 
al., 2002) 
IL10 
-1082G/A Spanish TB no association 
(Lopez-
Maderuelo et 
al., 2003) 
IL12 A/C 3'UTR Russian TB no association (Puzyrev et 
al., 2002) 
IL12RB1 
1: Q214-M365-
G378 /  
2: R214-T365-
R378 
Japanese TB 
allele 2 assoc with 
susceptibility & ↓ levels 
of IL-12-induced 
signalling 
(Akahoshi et 
al., 2003) 
mannose-
binding lectin polymorphisms   TB association 
(Bellamy, 
2000) 
MCP1 -2518G Mexican TB association 
(Flores-
Villanueva et 
al., 2005) 
NAT2 NAT2 "fast" 
allele African TB high prevalence 
(Adams et 
al., 2003) 
NLI-IF (close to 
NRAMP1) 
204C→A, 
402T→C,  
472-42G→A 
Caucasian TB no association (Ma et al., 2002b) 
NOS2 NOS2(-/-) mice TB highly susceptible (MacMicking 
et al., 1997) 
Japanese TB 
(A) TB patients more 
likely to develop 
cavitary lesion 
(Abe et al., 
2003) 
Cambodian TB heterozygosity assoc 
with resistance 
(Delgado et 
al., 2002) 
  
tuberculous 
pleurisy no association 
(Kim et al., 
2003) 
NRAMP1 / 
SLC11A1 D543N 
Taiwanese TB no association (Liaw et al., 2002) 
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Danish TB no association (Soborg et 
al., 2002) 
Gambian TB association (Bellamy et 
al., 1998b) 
Cambodian TB heterozygosity assoc 
with resistance 
(Delgado et 
al., 2002) 
  
tuberculous 
pleurisy association 
(Kim et al., 
2003) 
Gambian TB association (Bellamy et 
al., 1998b) 
Korean TB association (Ryu et al., 2000) 
W Africa leprosy assoc with leprosy type (Meisner et 
al., 2001) 
Danish TB no association (Soborg et 
al., 2002) 
Guinea-
Conakry TB no association 
(Cervino et 
al., 2000) 
Taiwanese TB no association (Liaw et al., 2002) 
TGTG del 3' 
untrans. 
(1729+55del4, 
3'UTR) 
Bengali leprosy no association (Roy et al., 1999) 
  
tuberculous 
pleurisy association 
(Kim et al., 
2003) 
Guinea-
Conakry TB significant association 
(Cervino et 
al., 2000) 
Danish TB ↑ mycobacterial 
replication 
(Soborg et 
al., 2002) 
Gambian TB association (Bellamy et 
al., 1998b) 
Russian TB no association (Puzyrev et 
al., 2002) 
W African leprosy no association (Meisner et 
al., 2001) 
Bengali leprosy no association (Roy et al., 1999) 
469+14G/C 
(INT4) 
Cambodian TB uncommon in cohort (Delgado et 
al., 2002) 
Danish TB ↑ mycobacterial 
replication 
(Soborg et 
al., 2002) 
5'(CA)n 
(influences 
expression) 
AfrAm sarcoidosis protective (Maliarik et 
al., 2000) 
 161 
Gambian TB association (Bellamy et 
al., 1998b) 
Caucasian 
(Texas) TB 
association (HIV- and 
HIV+) 
(Ma et al., 
2002a) 
Gambian TB 
allele 2 assoc with 
susceptibility &  LPS-
induced production of 
IL-10 
(Bellamy et 
al., 1998b) 
W African leprosy no association (Meisner et 
al., 2001) 
Bengali leprosy no association (Roy et al., 1999) 
Guinea-
Conakry TB no association 
(Cervino et 
al., 2000) 
Taiwanese TB no association (Liaw et al., 2002) 
274C/T 
Russian TB no association (Puzyrev et 
al., 2002) 
-236C/T Cambodian TB uncommon in cohort (Delgado et 
al., 2002) 
microsatellite 
(exon 2) Bengali leprosy no association 
(Roy et al., 
1999) 
577-18G/A Taiwanese TB no association (Liaw et al., 2002) 
1465-85G/A Russian TB no association (Puzyrev et 
al., 2002) 
A318V Taiwanese TB no association (Liaw et al., 2002) 
microsatellite Brazilian TB/Lsh no linkage (Blackwell et 
al., 1997) 
coding region Japanese MAC 
no variations found 
assoc with 
susceptibility 
(Tanaka et 
al., 2000) 
Gly105-
>Asp105 mice BCG sensitive 
(Malo et al., 
1994) 
polymorphism rhesus 
macaque TB no association 
(Deinard et 
al., 2002) 
3'UTR (SSCP 
analysis) cattle M bovis 
no association with 
resistance/susceptibility 
(Barthel et 
al., 2000) 
-1269, -1140,     
-838, -298 Gambian TB no association 
(Li et al., 
2002) P2RX7 
-762 Gambian TB protective (Li et al., 2002) 
 162 
1513A->C Gambian TB CC-loss of function; no 
association 
(Li et al., 
2002) 
    RSV & TB implicated in 
susceptibility 
(Haataja & 
Hallman, 
2002) 
SP-A1C1416T Indian TB association (Madan et 
al., 2002) 
SP-A2C1382G Indian TB association (Madan et 
al., 2002) 
SP-A 
SNPA1660G + 
SP-A2G1649C Indian TB association 
(Madan et 
al., 2002) 
SP-D     RSV & TB implicated in 
susceptibility 
(Haataja & 
Hallman, 
2002) 
-308 Bashkorto-
stan TB allele 2 ↑ in TB patients 
(Bikmaeva et 
al., 2002) 
-1030 Cambodian TB no association (Delgado et 
al., 2002) 
-862 Cambodian TB no association (Delgado et 
al., 2002) 
-856 Cambodian TB no association (Delgado et 
al., 2002) 
-375 Cambodian TB no association (Delgado et 
al., 2002) 
-307 Cambodian TB no association (Delgado et 
al., 2002) 
-243 Cambodian TB no association (Delgado et 
al., 2002) 
-237 Cambodian TB no association (Delgado et 
al., 2002) 
RFLP Cambodian TB no association (Goldfeld et 
al., 1998) 
-238   TB no association (Selvaraj et 
al., 2001) 
TNFA 
-308   TB no association (Selvaraj et 
al., 2001) 
TNFB NcoI   TB no association (Selvaraj et 
al., 2001) 
TNFSF5 (CD40 
ligand) 
6 SNPs & 
microsatellite. W African TB no association 
(Campbell et 
al., 2003) 
UBE3A 
7 bp del 
promoter 
region 
W African;  
S African TB association 
(Cervino et 
al., 2002) 
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polymorphisms   TB association 
(Bellamy & 
Hill, 1998); 
(Bellamy, 
2000)  
codon 352 Gambian TB TT underrepresented (Bellamy et 
al., 1999) 
  Bengali leprosy association with leprosy type 
(Roy et al., 
1999) 
C/T 
polymorphism 
Chinese 
Han TB 
VDR-ff genotype might 
be assoc with 
susceptibility 
(Liu et al., 
2003) 
TaqI/FokI Cambodian TB no association (Delgado et 
al., 2002) 
VDR 
TaqI/BsmI/FokI Gujarati TB 
polymorphisms may 
contribute to 
susceptibility (in 
combination with 25-
hydroxycholecalciferol 
deficiency) 
(Wilkinson et 
al., 2000) 
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Appendix E 
Genomic DNA sequences 
 
 
CCL3 and CCL3L1 genomic DNA sequences (see following page). 
Genbank accession numbers D90144 (α; CCL3) and D90145 (β; CCL3L1) 
(adapted from (Nakao et al., 1990)). 
 
Exons are in capitals.  Where CCL3L1 sequences are identical to CCL3, 
nucleotides are marked with dashes.  Transcription initiation site is +1, 
termination site is Ter.  The TATA box and polyadenylation signal are boxed. 
PCR primer sites are highlighted in yellow, probe in green. 
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Primer B
Primer A
Real-time PCR primer F Real-time PCR primer RReal-time PCR probe
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IL8 genomic DNA sequence (encoding CXCL8)  
(Genbank accession number AF385628).   
 
Exons are in capitals; IL8-251A/T polymorphism and start codon are in bold 
type. Real-time PCR primer and probe sites are marked. 
 
 
2761 cctcccaccc caaccaagca gctccagtgc accactttct ggagcataaa cataccttaa 
2821 ctttacaact tgagtggcct tgaatactgt tcctatctgg aatgtgctgt tctctttcat 
2881 cttcctctat tgaagccctc ctattcctca atgccttgct ccaactgcct ttggaagatt 
2941 ctgctcttat gcctccactg gaattaatgt cttagtacca cttgtctatt ctgctatata 
3001 gtcagtcctt acattgcttt cttcttctga tagaccaaac tctttaagga caagtaccta 
3061 gtcttatcta tttctagatc ccccacatta ctcagaaagt tactccataa atgtttgtgg 
         IL8-251 cons1 
3121 aactgatttc tatgtgaagc acatgtgccc cttcactctg ttaacatgca ttagaaaact 
3181 aaatcttttg aaaagttgta gtatgccccc taagagcagt aacagaaact aagagttcct 
3241 agaaactctc taaaatgctt agaaaaagat ttattttaaa ttacctcccc aataaaatga 
     IL8-251 cons2 
3301 ttggctggct tatcttcacc atcatgatag catctgtaat taactgaaaa aaaataatta 
3361 tgccattaaa agaaaatcat ccatgatctt gttctaacac ctgccactct agtactatat 
          IL8-251A/T 
3421 ctgtcacatg gtactatgat aaagttatct agaaataaaa aagcatacaa ttgataattc 
3481 accaaattgt ggagcttcag tattttaaat gtatattaaa attaaattat tttaaagatc 
3541 aaagaaaact ttcgtcatac tccgtatttg ataaggaaca aataggaagt gtgatgactc 
3601 aggtttgccc tgaggggatg ggccatcagt tgcaaatcgt ggaatttcct ctgacataat 
3661 gaaaagatga gggtgcataa gttctctagt agggtgatga tataaaaagc caccggagca 
3721 ctccataagg cacaaacttt cagagacAGC AGAGCACACA AGCTTCTAGG ACAAGAGCCA 
3781 GGAAGAAACC ACCGGAAGGA ACCATCTCAC TGTGTGTAAA CATGACTTCC AAGCTGGCCG 
3841 TGGCTCTCTT GGCAGCCTTC CTGATTTCTG CAGCTCTGTG TGAAGgtaag cacatctttc 
3901 tgacctacag cgttttccta tgtctaaatg tgatccttag atagcaaagc tattcttgat 
3961 gctttggtaa caaacatcct ttttattcag aaacagaata taatcttagc agtcaattaa 
4021 tgttaaattg aagatttaga aaaaactata tataacactt aggaaagtat aaagtttgat 
4081 caatatagat attctgcttt tataatttat accatgtagc atgcatatat ttaacgtaaa 
4141 taagtaattt atagtatgtc ctattgagaa ccacggttac ctatattatg tattaatatt 
4201 gagttgagca aggtaactca gacaattcca ctccttgtag tatttcattg acaagcctca 
4261 gatttgtcat taattcctgt ctggtttaaa gataccctga ttatagacca ggcatgtata 
4321 acttatttat atatttctgt taattctttc tgaaggcaat ttctatgctg gagagtctta 
4381 gcttgcctac tataaataac actgtggtat cacagaggat tatgcaatat tgaccagata 
4441 aaaataccat gaagatgttg atattgtaca aaaagaactc taactcttta tataggaagt 
4501 cgttcaatgt tgtcagttat gactgttttt taaaacaaag aactaactga ggtcaagggc 
4561 taggagaata ttcaggaatg agttcactag aaacatgatg ccttccatag tctccaaata 
4621 atcatattgg aattagaaag gaagtagctg gcagagctgt gcctgttgat aaaatcaatc 
4681 cttaatcact ttttccccca acaggTGCAG TTTTGCCAAG GAGTGCTAAA GAACTTAGAT 
4741 GTCAGTGCAT AAAGACATAC TCCAAACCTT TCCACCCCAA ATTTATCAAA GAACTGAGAG 
4801 TGATTGAGAG TGGACCACAC TGCGCCAACA CAGAAATTAT GTAAgtactt taaaaaagat 
4861 tagatatttt gttttagcaa acttaaaatt aaggaaggtg gaaatattta ggaaagttcc 
4921 aggtgttagg attacagtag taaatgaaac aaaacaaaat aaaaaatatt tgtctacatg 
4981 acatttaaat atggtagctt ccacaactac tataaatgtt attttggact tagactttat 
5041 gcctgactta aggaatcatg atttgaatgc aaaaactaaa tattaatctg aaccatttct 
5101 ttcttatttc agtgtaaagC TTTCTGATGG AAGAGAGCTC TGTCTGGACC CCAAGGAAAA 
5161 CTGGGTGCAG AGGGTTGTGG AGAAGTTTTT GAAGAGgtaa gttatatatt ttttaattta 
5221 aatttttcat ttatcctgag acatataatc caaagtcagc ctataaattt ctttctgttg 
5281 ctaaaaatcg tcattaggta tctgcctttt tggttaaaaa aaaaaggaat agcatcaata 
5341 gtgagtttgt tgtactcatg accagaaaga ccatacatag tttgcccagg aaattctggg 
5401 tttaagcttg tgtcctatac tcttagtaaa gttctttgtc actcccagta gtgtcctatt 
5461 ttagatgata atttctttga tctccctatt tatagttgag aatatagagc atttctaaca 
5521 catgaatgtc aaagactata ttgacttttc aagaacccta ctttccttct tattaaacat 
5581 agctcatctt tatattttta atTTTATTTT AGGGCTGAGA ATTCATAAAA AAATTCATTC 
5641 TCTGTGGTAT CCAAGAATCA GTGAAGATGC CAGTGAAACT TCAAGCAAAT CTACTTCAAC 
5701 ACTTCATGTA TTGTGTGGGT CTGTTGTAGG GTTGCCAGAT GCAATACAAG ATTCCTGGTT 
5761 AAATTTGAAT TTCAGTAAAC AATGAATAGT TTTTCATTGT ACCATGAAAT ATCCAGAACA 
5821 TACTTATATG TAAAGTATTA TTTATTTGAA TCTACAAAAA ACAACAAATA ATTTTTAAAT 
5881 ATAAGGATTT TCCTAGATAT TGCACGGGAG AATATACAAA TAGCAAAATT GAGGCCAAGG 
5941 GCCAAGAGAA TATCCGAACT TTAATTTCAG GAATTGAATG GGTTTGCTAG AATGTGATAT 
6001 TTGAAGCATC ACATAAAAAT GATGGGACAA TAAATTTTGC CATAAAGTCA AATTTAGCTG 
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6061 GAAATCCTGG ATTTTTTTCT GTTAAATCTG GCAACCCTAG TCTGCTAGCC AGGATCCACA 
6121 AGTCCTTGTT CCACTGTGCC TTGGTTTCTC CTTTATTTCT AAGTGGAAAA AGTATTAGCC 
6181 ACCATCTTAC CTCACAGTGA TGTTGTGAGG ACATGTGGAA GCACTTTAAG TTTTTTCATC 
6241 ATAACATAAA TTATTTTCAA GTGTAACTTA TTAACCTATT TATTATTTAT GTATTTATTT 
6301 AAGCATCAAA TATTTGTGCA AGAATTTGGA AAAATAGAAG ATGAATCATT GATTGAATAG 
6361 TTATAAAGAT GTTATAGTAA ATTTATTTTA TTTTAGATAT TAAATGATGT TTTATTAGAT 
6421 AAATTTCAAT CAGGGTTTTT AGATTAAACA AACAAACAAT TGGGTACCCA GTTAAATTTT 
6481 CATTTCAGAT AAACAACAAA TAATTTTTTA GTATAAGTAC ATTATTGTTT ATCTGAAATT 
6541 TTAATTGAAC TAACAATCCT AGTTTGATAC TCCCAGTCTT GTCATTGCCA GCTGTGTTGG 
6601 TAGTGCTGTG TTGAATTACG GAATAATGAG TTAGAACTAT TAAAACAGCC AAAACTCCAC 
6661 AGTCAATATT AGTAATTTCT TGCTGGTTGA AACTTGTTTA TTATGTACAA ATAGATTCTT 
6721 ATAATATTAT TTAAATGACT GCATTTTTAA ATACAAGGCT TTATATTTTT AACTTTAAGA 
6781 TGTTTTTATG TGCTCTCCAA ATTTTTTTTA CTGTTTCTGA TTGTATGGAA ATATAAAAGT 
6841 AAATATGAAA CATTTAAAAT ATAATTTGTT GTCAAAGTAA tcaagtgttt gtcttttttt 
6901 tagttttagc ttattgggat tctctttgtt tatatttaaa attatacttt gatttagaaa 
6961 acataaatgc ttccccttag cattttgttt atggaaaatt acaaactttt atttttagaa 
7021 aacagaactc ctttccagaa ataggttaca aacagtagtg tcctccacag aatgttggaa 
7081 atgttttcaa ctccccactg tatactatct tgctaataag tctgtcttca gatttcgatt 
7141 aaccggtttg tatgtc 
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Appendix F 
List of suppliers 
 
 
ABI Prism 3100 Genetic Analyser  Applied Biosystems, Foster City, California, USA 
ABI PRISM 7500  Applied Biosystems 
agarose Bioline, London, UK 
BigDye® Terminator v3.1 Cycle 
Sequencing Kit Applied Biosystems 
dNTPs Promega Corporation, Madison, Wisconsin, USA 
DuoSet ELISA Development Systems R&D Systems, Minneapolis, Minnesota, USA 
EDTA Vacutainers  Becton Dickinson, San Jose, California, USA 
Electro-Fast Stretch 108 Gel Tank System ABgene Ltd., Epsom, UK 
ethanol  Merck Chemicals (Pty) Ltd, Nottingham, UK 
ethidium bromide  CLP, San Diego, California, USA 
Expand High Fidelity enzyme and buffer Roche Diagnostics GmbH, Mannheim, Germany 
Ficoll-Paque  Amersham Biosciences, Uppsala, Sweden 
GeneAmp PCR System 9700 Applied Biosystems 
MgCl2  Promega Corporation 
NanoDrop NanoDrop Technologies, Wilmington, Detroit, USA 
PCR primers and probes  University of Cape Town, South Africa 
PHA Sigma Chemical Co., St Louis, Missouri, USA 
QIAamp DNA Blood Minikit  QIAgen, Hilden, Germany 
QIAquick PCR Purification Kit  QIAgen 
Quantikine ELISA kits R&D Systems 
RPMI medium Invitrogen Corporation, Carlsbad, California, USA 
sodium acetate  Merck  
SPSS version 15.0  SPSS Inc., Chicago, Illinois, USA 
SYBR Green  Applied Biosystems 
Taq DNA polymerase and buffer Promega Corporation 
TaqMan Universal PCR Master Mix Applied Biosystems 
TBE Invitrogen Corporation 
trypan blue  Sigma 
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Appendix G 
Ethical clearance 
 
 
